| Year |
Citation |
Score |
| 2023 |
Parker CS, Zhou L, Prabhu VV, Lee S, Miner TJ, Ross EA, El-Deiry WS. ONC201/TIC10 plus TLY012 anti-cancer effects via apoptosis inhibitor downregulation, stimulation of integrated stress response and death receptor DR5 in gastric adenocarcinoma. American Journal of Cancer Research. 13: 6290-6312. PMID 38187068 |
0.404 |
|
| 2023 |
Chang WI, Honeyman JN, Zhang J, Lin C, Sharma A, Zhou L, Oliveira J, Tapinos N, Lulla RR, Prabhu VV, El-Deiry WS. Novel combination of imipridones and histone deacetylase inhibitors demonstrate cytotoxic effect through integrated stress response in pediatric solid tumors. American Journal of Cancer Research. 13: 6241-6255. PMID 38187038 |
0.348 |
|
| 2023 |
Tummala T, Sevilla Uruchurtu AS, Cruz A, Huntington KE, George A, Liguori NR, Zhang L, Zhou L, Abbas AE, Azzoli CG, El-Deiry WS. Preclinical Synergistic Combination Therapy of Lurbinectedin with Irinotecan and 5-Fluorouracil in Pancreatic Cancer. Current Oncology (Toronto, Ont.). 30: 9611-9626. PMID 37999116 DOI: 10.3390/curroncol30110696 |
0.346 |
|
| 2023 |
Carlsen L, Zhang S, Tian X, De La Cruz A, George A, Arnoff TE, El-Deiry WS. The role of p53 in anti-tumor immunity and response to immunotherapy. Frontiers in Molecular Biosciences. 10: 1148389. PMID 37602328 DOI: 10.3389/fmolb.2023.1148389 |
0.356 |
|
| 2023 |
Huntington KE, Louie AD, Srinivasan PR, Schorl C, Lu S, Silverberg D, Newhouse D, Wu Z, Zhou L, Borden BA, Giles FJ, Dooner M, Carneiro BA, El-Deiry WS. GSK-3 Inhibitor Elraglusib Enhances Tumor-Infiltrating Immune Cell Activation in Tumor Biopsies and Synergizes with Anti-PD-L1 in a Murine Model of Colorectal Cancer. International Journal of Molecular Sciences. 24. PMID 37446056 DOI: 10.3390/ijms241310870 |
0.317 |
|
| 2023 |
Vitale I, Pietrocola F, Guilbaud E, Aaronson SA, Abrams JM, Adam D, Agostini M, Agostinis P, Alnemri ES, Altucci L, Amelio I, Andrews DW, Aqeilan RI, Arama E, Baehrecke EH, ... ... El-Deiry WS, et al. Apoptotic cell death in disease-Current understanding of the NCCD 2023. Cell Death and Differentiation. PMID 37100955 DOI: 10.1038/s41418-023-01153-w |
0.541 |
|
| 2023 |
Huntington KE, Louie AD, Srinivasan PR, Schorl C, Lu S, Silverberg D, Newhouse D, Wu Z, Zhou L, Borden BA, Giles FJ, Dooner M, Carneiro BA, El-Deiry WS. GSK-3 inhibitor elraglusib enhances tumor-infiltrating immune cell activation in tumor biopsies and synergizes with anti-PD-L1 in a murine model of colorectal cancer. Biorxiv : the Preprint Server For Biology. PMID 36798357 DOI: 10.1101/2023.02.07.527499 |
0.315 |
|
| 2023 |
Di Cristofano FR, Fong MW, Huntington KE, Carneiro BA, Zhou L, El-Deiry WS. Synergistic activity of ABT-263 and ONC201/TIC10 against solid tumor cell lines is associated with suppression of anti-apoptotic Mcl-1, BAG3, pAkt, and upregulation of pro-apoptotic Noxa and Bax cleavage during apoptosis. American Journal of Cancer Research. 13: 307-325. PMID 36777502 |
0.427 |
|
| 2023 |
Gonzalez Z, Carlsen L, El-Deiry WS. Temozolomide combined with ipilimumab plus nivolumab enhances T cell killing of MGMT-expressing, MSS colorectal cancer cells. American Journal of Cancer Research. 13: 216-226. PMID 36777499 |
0.334 |
|
| 2022 |
Zhang S, Carlsen L, Hernandez Borrero L, Seyhan AA, Tian X, El-Deiry WS. Advanced Strategies for Therapeutic Targeting of Wild-Type and Mutant p53 in Cancer. Biomolecules. 12. PMID 35454137 DOI: 10.3390/biom12040548 |
0.36 |
|
| 2022 |
Liguori NR, Sanchez Sevilla Uruchurtu A, Zhang L, Abbas AE, Lee YS, Zhou L, Azzoli CG, El-Deiry WS. Preclinical studies with ONC201/TIC10 and lurbinectedin as a novel combination therapy in small cell lung cancer (SCLC). American Journal of Cancer Research. 12: 729-743. PMID 35261798 |
0.356 |
|
| 2022 |
Lulla AR, Zhou Y, Ralff MD, Lev A, Dicker DT, El-Deiry WS. miR-3132 upregulates surface TRAIL to induce apoptotic cell death in cancer cells. American Journal of Cancer Research. 12: 315-326. PMID 35141020 |
0.31 |
|
| 2022 |
Zhang S, Zhou L, El-Deiry WS. Small-Molecule NSC59984 Induces Mutant p53 Degradation through a ROS-ERK2-MDM2 Axis in Cancer Cells. Molecular Cancer Research : McR. PMID 34992144 DOI: 10.1158/1541-7786.MCR-21-0149 |
0.358 |
|
| 2021 |
Jhaveri AV, Zhou L, Ralff MD, Lee YS, Navaraj A, Carneiro BA, Safran H, Prabhu VV, Ross EA, Lee S, El-Deiry WS. Combination of ONC201 and TLY012 induces selective, synergistic apoptosis in vitro and significantly delays PDAC xenograft growth in vivo. Cancer Biology & Therapy. 22: 607-618. PMID 34856854 DOI: 10.1080/15384047.2021.1976567 |
0.435 |
|
| 2021 |
Carlsen L, El-Deiry WS. Differential p53-Mediated Cellular Responses to DNA-Damaging Therapeutic Agents. International Journal of Molecular Sciences. 22. PMID 34769259 DOI: 10.3390/ijms222111828 |
0.337 |
|
| 2021 |
Ray JE, Ralff MD, Jhaveri A, Zhou L, Dicker DT, Ross EA, El-Deiry WS. Antitumorigenic effect of combination treatment with ONC201 and TRAIL in endometrial cancer and . Cancer Biology & Therapy. 1-10. PMID 34696710 DOI: 10.1080/15384047.2021.1977067 |
0.411 |
|
| 2021 |
Zhao S, Zhou L, Dicker DT, Lev A, Zhang S, Ross E, El-Deiry WS. Anti-cancer efficacy including Rb-deficient tumors and VHL-independent HIF1α proteasomal destabilization by dual targeting of CDK1 or CDK4/6 and HSP90. Scientific Reports. 11: 20871. PMID 34686682 DOI: 10.1038/s41598-021-00150-8 |
0.35 |
|
| 2021 |
Allen JE, Kline CLB, Prabhu VV, Wagner J, Ishizawa J, Madhukar N, Lev A, Baumeister M, Zhou L, Lulla A, Stogniew M, Schalop L, Benes C, Kaufman HL, Pottorf RS, ... ... El-Deiry WS, et al. Correction: Discovery and clinical introduction of first-in-class imipridone ONC201. Oncotarget. 12: 2231. PMID 34676056 DOI: 10.18632/oncotarget.28012 |
0.336 |
|
| 2021 |
Sahin I, George A, Zhang S, Huntington KE, Ordulu Z, Zhou L, El-Deiry WS. Hyperprogression of a mismatch repair-deficient colon cancer in a humanized mouse model following administration of immune checkpoint inhibitor pembrolizumab. Oncotarget. 12: 2131-2146. PMID 34676046 DOI: 10.18632/oncotarget.28086 |
0.36 |
|
| 2021 |
Borsuk R, Zhou L, Chang WI, Zhang Y, Sharma A, Prabhu VV, Tapinos N, Lulla RR, El-Deiry WS. Potent preclinical sensitivity to imipridone-based combination therapies in oncohistone H3K27M-mutant diffuse intrinsic pontine glioma is associated with induction of the integrated stress response, TRAIL death receptor DR5, reduced ClpX and apoptosis. American Journal of Cancer Research. 11: 4607-4623. PMID 34659909 |
0.33 |
|
| 2021 |
Carlsen L, Schorl C, Huntington K, Hernandez-Borrero L, Jhaveri A, Zhang S, Zhou L, El-Deiry WS. Pan-drug and drug-specific mechanisms of 5-FU, irinotecan (CPT-11), oxaliplatin, and cisplatin identified by comparison of transcriptomic and cytokine responses of colorectal cancer cells. Oncotarget. 12: 2006-2021. PMID 34611476 DOI: 10.18632/oncotarget.28075 |
0.306 |
|
| 2021 |
Hernandez Borrero L, Dicker DT, Santiago J, Sanders J, Tian X, Ahsan N, Lev A, Zhou L, El-Deiry WS. A subset of CB002 xanthine analogs bypass p53-signaling to restore a p53 transcriptome and target an S-phase cell cycle checkpoint in tumors with mutated-p53. Elife. 10. PMID 34324416 DOI: 10.7554/eLife.70429 |
0.377 |
|
| 2021 |
Zhang Y, Zhou L, Safran H, Borsuk R, Lulla R, Tapinos N, Seyhan AA, El-Deiry WS. EZH2i EPZ-6438 and HDACi vorinostat synergize with ONC201/TIC10 to activate integrated stress response, DR5, reduce H3K27 methylation, ClpX and promote apoptosis of multiple tumor types including DIPG. Neoplasia (New York, N.Y.). 23: 792-810. PMID 34246076 DOI: 10.1016/j.neo.2021.06.007 |
0.365 |
|
| 2021 |
Ferrarini I, Louie A, Zhou L, El-Deiry WS. ONC212 is a novel mitocan acting synergistically with glycolysis inhibition in pancreatic cancer. Molecular Cancer Therapeutics. PMID 34224362 DOI: 10.1158/1535-7163.MCT-20-0962 |
0.304 |
|
| 2021 |
George A, Sahin I, Carneiro BA, Dizon DS, Safran HP, El-Deiry WS. Strategies to sensitize cancer cells to immunotherapy. Human Vaccines & Immunotherapeutics. 1-7. PMID 34019474 DOI: 10.1080/21645515.2021.1891817 |
0.32 |
|
| 2021 |
Hernández Borrero LJ, El-Deiry WS. Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting. Biochimica Et Biophysica Acta. Reviews On Cancer. 1876: 188556. PMID 33932560 DOI: 10.1016/j.bbcan.2021.188556 |
0.316 |
|
| 2021 |
Tian X, Ahsan N, Lulla A, Lev A, Abbosh P, Dicker DT, Zhang S, El-Deiry WS. P53-independent partial restoration of the p53 pathway in tumors with mutated p53 through ATF4 transcriptional modulation by ERK1/2 and CDK9. Neoplasia (New York, N.Y.). 23: 304-325. PMID 33582407 DOI: 10.1016/j.neo.2021.01.004 |
0.37 |
|
| 2020 |
Sikder RK, Ellithi M, Uzzo RN, Weader D, Metz AL, Behbahani A, McKenzie ER, El-Deiry WS, Abbosh PH. Differential effects of clinically-relevant N- vs C-terminal truncating CDKN1A mutations on cisplatin sensitivity in bladder cancer. Molecular Cancer Research : McR. PMID 33272936 DOI: 10.1158/1541-7786.MCR-19-1200 |
0.332 |
|
| 2020 |
Ralff MD, Jhaveri A, Ray JE, Zhou L, Lev A, Campbell KS, Dicker DT, Ross EA, El-Deiry WS. TRAIL receptor agonists convert the response of breast cancer cells to ONC201 from anti-proliferative to apoptotic. Oncotarget. 11: 3753-3769. PMID 33144917 DOI: 10.18632/oncotarget.27773 |
0.41 |
|
| 2020 |
Prabhu VV, Morrow S, Rahman Kawakibi A, Zhou L, Ralff M, Ray J, Jhaveri A, Ferrarini I, Lee Y, Parker C, Zhang Y, Borsuk R, Chang WI, Honeyman JN, Tavora F, ... ... El-Deiry WS, et al. ONC201 and imipridones: Anti-cancer compounds with clinical efficacy. Neoplasia (New York, N.Y.). 22: 725-744. PMID 33142238 DOI: 10.1016/j.neo.2020.09.005 |
0.599 |
|
| 2020 |
Francescone R, Barbosa Vendramini-Costa D, Franco-Barraza J, Wagner J, Muir A, Lau AN, Gabitova L, Pazina T, Gupta S, Luong T, Rollins D, Malik R, Thapa RJ, Restifo D, Zhou Y, ... ... El-Deiry WS, et al. Netrin G1 promotes pancreatic tumorigenesis through cancer associated fibroblast driven nutritional support and immunosuppression. Cancer Discovery. PMID 33127842 DOI: 10.1158/2159-8290.CD-20-0775 |
0.313 |
|
| 2020 |
Sahin I, Zhang S, Navaraj A, Zhou L, Dizon D, Safran H, El-Deiry WS. Correction: AMG-232 sensitizes high MDM2-expressing tumor cells to T-cell-mediated killing. Cell Death Discovery. 6: 71. PMID 32802408 DOI: 10.1038/S41420-020-00310-1 |
0.379 |
|
| 2020 |
Sahin I, Zhang S, Navaraj A, Zhou L, Dizon D, Safran H, El-Deiry WS. AMG-232 sensitizes high MDM2-expressing tumor cells to T-cell-mediated killing. Cell Death Discovery. 6: 57. PMID 32655895 DOI: 10.1038/S41420-020-0292-1 |
0.468 |
|
| 2020 |
Pei Y, Hwang N, Lang F, Zhou L, Wong JH, Singh RK, Jha HC, El-Deiry WS, Du Y, Robertson ES. Quassinoid analogs with enhanced efficacy for treatment of hematologic malignancies target the PI3Kγ isoform. Communications Biology. 3: 267. PMID 32461675 DOI: 10.1038/s42003-020-0996-z |
0.315 |
|
| 2020 |
Carneiro BA, El-Deiry WS. Targeting apoptosis in cancer therapy. Nature Reviews. Clinical Oncology. PMID 32203277 DOI: 10.1038/s41571-020-0341-y |
0.336 |
|
| 2019 |
Harrington CT, Sotillo E, Robert A, Hayer KE, Bogusz AM, Psathas J, Yu D, Taylor D, Dang CV, Klein PS, Hogarty MD, Geoerger B, El-Deiry WS, Wiels J, Thomas-Tikhonenko A. Correction: Transient stabilization, rather than inhibition, of MYC amplifies extrinsic apoptosis and therapeutic responses in refractory B-cell lymphoma. Leukemia. PMID 31758088 DOI: 10.1038/S41375-019-0650-2 |
0.604 |
|
| 2019 |
Stein MN, Malhotra J, Tarapore RS, Malhotra U, Silk AW, Chan N, Rodriguez L, Aisner J, Aiken RD, Mayer T, Haffty BG, Newman JH, Aspromonte SM, Bommareddy PK, Estupinian R, ... ... El-Deiry WS, et al. Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration. Journal For Immunotherapy of Cancer. 7: 136. PMID 31118108 DOI: 10.1186/S40425-019-0599-8 |
0.407 |
|
| 2019 |
Harrington CT, Sotillo E, Robert A, Hayer KE, Bogusz AM, Psathas J, Yu D, Taylor D, Dang CV, Klein P, Hogarty MD, Geoerger B, El-Deiry WS, Wiels J, Thomas-Tikhonenko A. Transient stabilization, rather than inhibition, of MYC amplifies extrinsic apoptosis and therapeutic responses in refractory B-cell lymphoma. Leukemia. PMID 30914792 DOI: 10.1038/s41375-019-0454-4 |
0.672 |
|
| 2019 |
Seeber A, Puccini A, Xiu J, Goldberg RM, Grothey A, Shields AF, Salem ME, Battaglin F, El-Deiry WS, Tokunaga R, Philip PA, Marshall J, Kocher F, Hall MJ, Korn WM, et al. Association of BRCA-mutant pancreatic cancer with high tumor mutational burden (TMB) and higher PD-L1 expression. Journal of Clinical Oncology. 37: 4133-4133. DOI: 10.1200/Jco.2019.37.15_Suppl.4133 |
0.342 |
|
| 2019 |
Spizzo G, Puccini A, Xiu J, Goldberg RM, Grothey A, Shields AF, Arora SP, Khushman MM, Salem ME, Battaglin F, El-Deiry WS, Tokunaga R, Philip PA, Hall MJ, Marshall J, et al. Frequency of BRCA mutation in biliary tract cancer and its correlation with tumor mutational burden (TMB) and microsatellite instability (MSI). Journal of Clinical Oncology. 37: 4085-4085. DOI: 10.1200/Jco.2019.37.15_Suppl.4085 |
0.37 |
|
| 2019 |
Seeber A, Kocher F, Xiu J, Spizzo G, Puccini A, Swensen J, Ellis M, Goldberg RM, Grothey A, Shields AF, Salem ME, Battaglin F, El-Deiry WS, Tokunaga R, Naseem M, et al. Molecular landscape of colorectal cancers harboring R-spondin fusions. Journal of Clinical Oncology. 37: 3588-3588. DOI: 10.1200/Jco.2019.37.15_Suppl.3588 |
0.411 |
|
| 2019 |
Puccini A, Xiu J, Goldberg RM, Grothey A, Shields AF, Salem ME, Seeber A, Battaglin F, Berger MD, El-Deiry WS, Tokunaga R, Naseem M, Zhang W, Arora SP, Khushman MM, et al. Molecular differences between lymph nodes (LNs) and distant metastases (mets) in colorectal cancer (CRC). Journal of Clinical Oncology. 37: 3130-3130. DOI: 10.1200/Jco.2019.37.15_Suppl.3130 |
0.378 |
|
| 2019 |
Borrero LJH, Lev A, Zhou L, Dicker DT, El-Deiry WS. Abstract 3878: Newly identified p53-pathway restoring small molecule, CB002 analog #4 induces apoptosis and appears non-toxicin vivo Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-3878 |
0.41 |
|
| 2019 |
Ralff MD, Ray JE, Lev A, Zhou L, Dicker DT, El-Deiry WS. Abstract 258: Recombinant human TRAIL or a DR5 agonistic antibody convert the response of non-triple negative breast cancer cells to ONC201 from anti-proliferative to apoptotic Cancer Research. 79: 258-258. DOI: 10.1158/1538-7445.Sabcs18-258 |
0.507 |
|
| 2019 |
Zhang Y, Zhou L, Zhang S, Ralff MD, Zhao S, Abbosh PH, Sidker R, El-Deiry WS. Abstract 5183: ONC201 induces acetylation of histone binding within the p21 (CDKN1A) gene promoter Cancer Research. 79: 5183-5183. DOI: 10.1158/1538-7445.Am2019-5183 |
0.431 |
|
| 2019 |
Zhou L, El-Deiry WS. Abstract 4808: Preclinical studies of the combination of ONC201, radiotherapy and Temozolomide against GBM, DIPG and ATRT cell lines Cancer Research. 79: 4808-4808. DOI: 10.1158/1538-7445.Am2019-4808 |
0.474 |
|
| 2019 |
Zhao S, Zhou L, Dicker DT, El-Deiry WS. Abstract 2654: Synergistic inhibition of cancer cell viability and suppression of HIF1α by CDK4 inhibitors and HSP90 inhibitors across cancer types Cancer Research. 79: 2654-2654. DOI: 10.1158/1538-7445.Am2019-2654 |
0.482 |
|
| 2019 |
Ray J, Ralff M, Dicker D, El-Deiry W. Abstract 262: Anti-tumorigenic effect of ONC201 is enhanced by combination treatment with TRAIL or a DR5 agonist in endometrial cancer in vitro Cancer Research. 79: 262-262. DOI: 10.1158/1538-7445.Am2019-262 |
0.531 |
|
| 2019 |
Zhang S, Zhou L, Ralff MD, El-Deiry WS. Abstract 2057: Small molecule CB001 induces extrinsic apoptosis via downregulation of c-FLIP expression in mutant p53-expressing cancer cells Cancer Research. 79: 2057-2057. DOI: 10.1158/1538-7445.Am2019-2057 |
0.538 |
|
| 2019 |
Zhou L, El-Deiry W. EXTH-57. PRECLINICAL COMBINATION OF ONC201 WITH RADIOTHERAPY OR TEMOZOLOMIDE IN GBM, DIPG AND ATRT CELL LINES RESULTS IN DOPAMINE RECEPTOR ANTAGONISM, ATF4 INDUCTION AND CELL DEATH Neuro-Oncology. 21: vi94-vi94. DOI: 10.1093/neuonc/noz175.388 |
0.396 |
|
| 2018 |
Ralff MD, El-Deiry WS. TRAIL pathway targeting therapeutics. Expert Review of Precision Medicine and Drug Development. 3: 197-204. PMID 30740527 DOI: 10.1080/23808993.2018.1476062 |
0.391 |
|
| 2018 |
Ghatalia P, Smith CH, Winer A, Gou J, Kiedrowski LA, Slifker M, Saltzberg PD, Bubes N, Anari FM, Kasireddy V, Varshavsky A, Liu Y, Ross EA, El-Deiry WS. Clinical Utilization Pattern of Liquid Biopsies (LB) to Detect Actionable Driver Mutations, Guide Treatment Decisions and Monitor Disease Burden During Treatment of 33 Metastatic Colorectal Cancer (mCRC) Patients (pts) at a Fox Chase Cancer Center GI Oncology Subspecialty Clinic. Frontiers in Oncology. 8: 652. PMID 30705875 DOI: 10.3389/Fonc.2018.00652 |
0.319 |
|
| 2018 |
Prabhu VV, Madhukar NS, Gilvary C, Kline CLB, Oster S, El-Deiry WS, Elemento O, Doherty FC, VanEngelenburg A, Durrant J, Tarapore RS, Deacon S, Charter N, Jung J, Park DM, et al. Dopamine Receptor D5 is a Modulator of Tumor Response to Dopamine Receptor D2 Antagonism. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30559168 DOI: 10.1158/1078-0432.Ccr-18-2572 |
0.498 |
|
| 2018 |
Hernandez Borrero LJ, Sikder R, Lulla A, Gokare P, Del Valle PR, Tian X, Zhang S, Abbosh PH, El-Deiry WS. Bcl-2 Protein Targeting by the p53/p21 Complex-Letter. Cancer Research. PMID 29703721 DOI: 10.1158/0008-5472.Can-17-2556 |
0.435 |
|
| 2018 |
Lev A, Lulla AR, Ross BC, Ralff MD, Makhov PB, Dicker DT, El-Deiry WS. ONC201 Targets AR and AR-V7 Signaling, Reduces PSA, and Synergizes with Everolimus in Prostate Cancer. Molecular Cancer Research : McR. PMID 29588330 DOI: 10.1158/1541-7786.Mcr-17-0614 |
0.339 |
|
| 2018 |
Wagner J, Kline CL, Zhou L, Campbell KS, MacFarlane AW, Olszanski AJ, Cai KQ, Hensley HH, Ross EA, Ralff MD, Zloza A, Chesson CB, Newman JH, Kaufman H, Bertino JR, ... ... El-Deiry W, et al. Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment. The Journal of Clinical Investigation. PMID 29533922 DOI: 10.1172/Jci96711 |
0.468 |
|
| 2018 |
Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, Nathenson M, Doebele RC, Farago AF, Pappo AS, Turpin B, Dowlati A, Brose MS, Mascarenhas L, Federman N, ... ... El-Deiry WS, et al. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. The New England Journal of Medicine. 378: 731-739. PMID 29466156 DOI: 10.1056/Nejmoa1714448 |
0.315 |
|
| 2018 |
Matthew EM, Yang Z, Peri S, Andrake M, Dunbrack R, Ross E, El-Deiry WS. Plk2 Loss Commonly Occurs in Colorectal Carcinomas but not Adenomas: Relationship to mTOR Signaling. Neoplasia (New York, N.Y.). 20: 244-255. PMID 29448085 DOI: 10.1016/J.Neo.2018.01.004 |
0.401 |
|
| 2018 |
Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P, Alnemri ES, Altucci L, Amelio I, Andrews DW, Annicchiarico-Petruzzelli M, Antonov AV, Arama E, Baehrecke EH, Barlev NA, ... ... El-Deiry WS, et al. Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death and Differentiation. PMID 29362479 DOI: 10.1038/S41418-017-0012-4 |
0.589 |
|
| 2018 |
Wagner J, Kline CL, Zhou L, Khazak V, El-Deiry WS. Anti-tumor effects of ONC201 in combination with VEGF-inhibitors significantly impacts colorectal cancer growth and survival in vivo through complementary non-overlapping mechanisms. Journal of Experimental & Clinical Cancer Research : Cr. 37: 11. PMID 29357916 DOI: 10.1186/S13046-018-0671-0 |
0.421 |
|
| 2018 |
Stein MN, Malhotra J, Malhotra U, Silk AW, Chan N, Rodriguez-Rodriguez L, Aisner J, Aiken R, Newman J, Sadimin E, Saunders T, Frankel M, Kareddula A, El-Deiry WS, Tarapore R, et al. Safety and pharmacodynamics of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration. Journal of Clinical Oncology. 36: 2595-2595. DOI: 10.1200/Jco.2018.36.15_Suppl.2595 |
0.525 |
|
| 2018 |
Ghatalia P, Winer A, Smith C, Gou J, Kiedrowski LA, Saltzberg PD, Bubes N, Anari F, Kasireddy V, Varshavsky A, Ross EA, El-Deiry WS. Liquid biopsies (LB) across treatment of 29 metastatic colorectal cancer (mCRC) patients (pts) to reveal driver mutations and tumor evolution with anti-EGFR therapy: Experience in a GI oncology clinic at Fox Chase Cancer Center. Journal of Clinical Oncology. 36: 12047-12047. DOI: 10.1200/Jco.2018.36.15_Suppl.12047 |
0.346 |
|
| 2018 |
Ralff, Kline C, El-Deiry W. Abstract P3-06-08: Imipridone compounds inhibit breast cancer mTORC1 signaling through integrated stress response-mediated upregulation of endogenous mTORC1 inhibitor sestrin2 Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-P3-06-08 |
0.449 |
|
| 2018 |
Ralff MD, Wagner J, El-Deiry WS. Abstract LB-082: ONC201 sensitizes resistant breast cancer cells to TRAIL through death receptor 5 upregulation Cancer Research. 78. DOI: 10.1158/1538-7445.Am2018-Lb-082 |
0.494 |
|
| 2018 |
Borrero LJH, Dicker DT, El-Deiry WS. Abstract 4828: Newly identified p53 pathway-restoring compound CB002 and its derivatives sensitize colorectal and multiple myeloma cancer cell lines to front-line cancer therapies Cancer Research. 78: 4828-4828. DOI: 10.1158/1538-7445.Am2018-4828 |
0.467 |
|
| 2018 |
Lulla AR, Lev A, Slifker M, Dicker DT, El-Deiry WS. Abstract 4289: Involvement of the miR-6883 family and the circadian rhythm gene PER1 in the DNA damage response (DDR) and chemosensitivity Cancer Research. 78: 4289-4289. DOI: 10.1158/1538-7445.Am2018-4289 |
0.368 |
|
| 2018 |
Sikder RK, El-Deiry WS, Abbosh PH. Abstract 405: PBRM1 re-introduction in PBRM1-mutant kidney cancer cell lines drives an Interferon-γ expression signature Cancer Research. 78: 405-405. DOI: 10.1158/1538-7445.Am2018-405 |
0.487 |
|
| 2018 |
Zhang S, Zhou L, El-Deiry WS. Abstract 3950: Small molecule NSC59984 synergizes with ROS-generating agents to induce cell death via reduced GSH in cancer cells Cancer Research. 78: 3950-3950. DOI: 10.1158/1538-7445.Am2018-3950 |
0.541 |
|
| 2018 |
Prabhu VV, Madhukar N, Kline CLB, Tarapore R, El-Deiry WS, Rucker J, Doranz B, Doherty F, VanEngelenburg A, Durrant J, Benes C, Deacon S, Charter N, Free RB, Oster W, et al. Abstract 3857: Selective targeting of dopamine receptor dysregulation in high grade gliomas with imipridone ONC201 Cancer Research. 78: 3857-3857. DOI: 10.1158/1538-7445.Am2018-3857 |
0.537 |
|
| 2018 |
Carnell MA, Feldman R, Atkins MB, El-Deiry WS, Pishvaian MJ, Salem ME, VanderWalde AM. Abstract 3618: Gene mutation and protein co-expression in melanoma and colorectal cancer by BRAF V600 mutation status Cancer Research. 78: 3618-3618. DOI: 10.1158/1538-7445.Am2018-3618 |
0.339 |
|
| 2018 |
Zhou L, Meng F, Anasori B, Gogotsi Y, El-Deiry WS. Abstract 3210: Photothermal therapy of malignant mesothelioma with delaminated MXene Ti3C2 Cancer Research. 78: 3210-3210. DOI: 10.1158/1538-7445.Am2018-3210 |
0.369 |
|
| 2018 |
Zhou L, Wagner J, El-Deiry WS. Abstract 2933: Synergistic antitumor effect of ONC201 in combination with radiation therapy Cancer Research. 78: 2933-2933. DOI: 10.1158/1538-7445.Am2018-2933 |
0.395 |
|
| 2018 |
Zhao S, Zhou L, Dicker DT, El-Deiry WS. Abstract 2436: Anti-cancer effect by combination treatment of CDK and HSP90 inhibitors through HIF1α inhibition Cancer Research. 78: 2436-2436. DOI: 10.1158/1538-7445.Am2018-2436 |
0.473 |
|
| 2018 |
Sikder RK, El-Deiry WS, Abbosh PH. Abstract 2307: Differential effects of N-terminal vs C-terminal truncating CDKN1A mutations on cisplatin resistance in bladder cancer Cancer Research. 78: 2307-2307. DOI: 10.1158/1538-7445.Am2018-2307 |
0.462 |
|
| 2018 |
Prabhu VV, Madhukar N, Kline CLB, Tarapore R, El-Deiry W, Elemento O, Doherty F, VanEngelenburg A, Durrant J, Zloza A, Benes C, Arrillaga I, Oster W, Allen JE. Abstract A060: Targeting DRD2 dysregulation in recurrent glioblastoma with imipridone ONC201: predictive and pharmacodynamic clinical biomarker analyses Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-A060 |
0.601 |
|
| 2018 |
Vijay Prabhu V, Madhukar N, Gilvary C, Kline CLB, Tarapore R, El-Deiry W, Doherty F, VanEngelenburg A, Durrant J, Benes C, Oster W, Elemento O, Allen J. DRES-10. DRD5 IS A MODULATOR OF GLIOMA SUSCEPTIBILITY TO DRD2 ANTAGONISM BY ONC201 Neuro-Oncology. 20: vi77-vi78. DOI: 10.1093/Neuonc/Noy148.317 |
0.423 |
|
| 2018 |
Abbosh P, Liu D, Ibragimova I, Rosenberg J, Ford J, El-Deiry W, Parker D, Geynisman D, Alpaugh RK, Cairns P, Kutikov A, Van Allen E, Plimack E. MP41-04 URINARY CORRELATES OF PATHOLOGIC COMPLETE RESPONSE IN BLADDER CANCER PATIENTS RECEIVING NEOADJUVANT CHEMOTHERAPY Journal of Urology. 199. DOI: 10.1016/J.Juro.2018.02.1291 |
0.306 |
|
| 2017 |
Ralff MD, Lulla AR, Wagner J, El-Deiry WS. ONC201: a new treatment option being tested clinically for recurrent glioblastoma. Translational Cancer Research. 6: S1239-S1243. PMID 30175049 DOI: 10.21037/Tcr.2017.10.03 |
0.386 |
|
| 2017 |
Kline CLB, Ralff MD, Lulla AR, Wagner JM, Abbosh PH, Dicker DT, Allen JE, El-Deiry WS. Role of Dopamine Receptors in the Anticancer Activity of ONC201. Neoplasia (New York, N.Y.). 20: 80-91. PMID 29216597 DOI: 10.1016/J.Neo.2017.10.002 |
0.576 |
|
| 2017 |
Prabhu VV, Talekar MK, Lulla AR, Kline CLB, Zhou L, Hall J, Van den Heuvel APJ, Dicker DT, Babar J, Grupp SA, Garnett MJ, McDermott U, Benes CH, Pu JJ, Claxton DF, ... ... El-Deiry WS, et al. Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies. Cell Cycle (Georgetown, Tex.). 1-29. PMID 29157092 DOI: 10.1080/15384101.2017.1403689 |
0.567 |
|
| 2017 |
Salem ME, Weinberg BA, Xiu J, El-Deiry WS, Hwang JJ, Gatalica Z, Philip PA, Shields AF, Lenz HJ, Marshall JL. Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers. Oncotarget. 8: 86356-86368. PMID 29156800 DOI: 10.18632/Oncotarget.21169 |
0.364 |
|
| 2017 |
Lev A, Lulla AR, Wagner J, Ralff MD, Kiehl JB, Zhou Y, Benes CH, Prabhu VV, Oster W, Astsaturov I, Dicker DT, El-Deiry WS. Anti-pancreatic cancer activity of ONC212 involves the unfolded protein response (UPR) and is reduced by IGF1-R and GRP78/BIP. Oncotarget. 8: 81776-81793. PMID 29137221 DOI: 10.18632/Oncotarget.20819 |
0.423 |
|
| 2017 |
Lulla AR, Slifker MJ, Zhou Y, Lev A, Einarson MB, Dicker DT, El-Deiry WS. miR-6883 family miRNAs target CDK4/6 to induce G1 phase cell cycle arrest in colon cancer cells. Cancer Research. PMID 29061672 DOI: 10.1158/0008-5472.Can-17-1767 |
0.31 |
|
| 2017 |
Finnberg NK, Gokare P, Lev A, Grivennikov SI, MacFarlane AW, Campbell KS, Winters RM, Kaputa K, Farma JM, Abbas AE, Grasso L, Nicolaides NC, El-Deiry WS. Application of 3D tumoroid systems to define immune and cytotoxic therapeutic responses based on tumoroid and tissue slice culture molecular signatures. Oncotarget. 8: 66747-66757. PMID 28977993 DOI: 10.18632/Oncotarget.19965 |
0.387 |
|
| 2017 |
Lev A, Deihimi S, Shagisultanova E, Xiu J, Lulla AR, Dicker DT, El-Deiry WS. Preclinical rationale for combination of crizotinib with mitomycin C for the treatment of advanced colorectal cancer. Cancer Biology & Therapy. 0. PMID 28886275 DOI: 10.1080/15384047.2017.1364323 |
0.447 |
|
| 2017 |
Zhou L, Dicker DT, Matthew E, El-Deiry WS, Alpaugh RK. Circulating tumor cells: silent predictors of metastasis. F1000research. 6. PMID 28868131 DOI: 10.12688/F1000Research.11313.1 |
0.37 |
|
| 2017 |
Gokare P, Finnberg NK, Abbosh PH, Dai J, Murphy ME, El-Deiry WS. P53 represses pyrimidine catabolic gene dihydropyrimidine dehydrogenase (DPYD) expression in response to thymidylate synthase (TS) targeting. Scientific Reports. 7: 9711. PMID 28851987 DOI: 10.1038/S41598-017-09859-X |
0.466 |
|
| 2017 |
Prabhu VV, Lulla AR, Madhukar NS, Ralff MD, Zhao D, Kline CLB, Van den Heuvel APJ, Lev A, Garnett MJ, McDermott U, Benes CH, Batchelor TT, Chi AS, Elemento O, Allen JE, ... El-Deiry WS, et al. Cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumors. Plos One. 12: e0180541. PMID 28767654 DOI: 10.1371/Journal.Pone.0180541 |
0.613 |
|
| 2017 |
Richardson C, Zhang S, Hernandez Borrero LJ, El-Deiry WS. Small-molecule CB002 restores p53 pathway signaling and represses colorectal cancer cell growth. Cell Cycle (Georgetown, Tex.). 0. PMID 28749206 DOI: 10.1080/15384101.2017.1356514 |
0.521 |
|
| 2017 |
Hernandez-Borrero LJ, Zhang S, Lulla A, Dicker DT, El-Deiry WS. CB002, a novel p53 tumor suppressor pathway-restoring small molecule induces tumor cell death through the pro-apoptotic protein NOXA. Cell Cycle (Georgetown, Tex.). 0. PMID 28749203 DOI: 10.1080/15384101.2017.1346762 |
0.547 |
|
| 2017 |
Ghatalia P, Nagarathinam R, Cooper H, Geynisman DM, El-Deiry WS. Mismatch repair deficient metastatic colon cancer and urothelial cancer: a case report of sequential immune checkpoint therapy. Cancer Biology & Therapy. 0. PMID 28726535 DOI: 10.1080/15384047.2017.1356506 |
0.355 |
|
| 2017 |
Deihimi S, Lev A, Slifker M, Shagisultanova E, Xu Q, Jung K, Vijayvergia N, Ross EA, Xiu J, Swensen J, Gatalica Z, Andrake M, Dunbrack RL, El-Deiry WS. BRCA2, EGFR, and NTRK mutations in mismatch repair-deficient colorectal cancers with MSH2 or MLH1 mutations. Oncotarget. PMID 28591715 DOI: 10.18632/Oncotarget.18098 |
0.31 |
|
| 2017 |
Wagner J, Kline CL, Ralff MD, Lev A, Lulla A, Zhou L, Olson GL, Nallaganchu BR, Benes CH, Allen JE, Prabhu VV, Stogniew M, Oster W, El-Deiry WS. Preclinical evaluation of the imipridone family, analogues of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212. Cell Cycle (Georgetown, Tex.). 0. PMID 28489985 DOI: 10.1080/15384101.2017.1325046 |
0.617 |
|
| 2017 |
Zhang J, Zhou L, Zhao S, Dicker DT, El-Deiry WS. The CDK4/6 inhibitor palbociclib synergizes with irinotecan to promote colorectal cancer cell death under hypoxia. Cell Cycle (Georgetown, Tex.). 0. PMID 28486050 DOI: 10.1080/15384101.2017.1320005 |
0.478 |
|
| 2017 |
Mirkin KA, Hollenbeak CS, Mohamed A, Jia Y, El-Deiry WS, Messaris E. Impact of perineural invasion on survival in node negative colon cancer. Cancer Biology & Therapy. 0. PMID 28475454 DOI: 10.1080/15384047.2017.1323602 |
0.328 |
|
| 2017 |
Ralff MD, Kline CLB, Küçükkase OC, Wagner J, Lim B, Dicker DT, Prabhu VV, Oster W, El-Deiry WS. ONC201 demonstrates anti-tumor effects in both triple negative and non-triple negative breast cancers through TRAIL-dependent and TRAIL-independent mechanisms. Molecular Cancer Therapeutics. PMID 28424227 DOI: 10.1158/1535-7163.Mct-17-0121 |
0.493 |
|
| 2017 |
Stein MN, Bertino JR, Kaufman HL, Mayer T, Moss R, Silk A, Chan N, Malhotra J, Rodriguez-Rodriguez L, Aisner J, Aiken RD, Haffty BG, DiPaola RS, Saunders T, Zloza A, ... ... El-Deiry WS, et al. First-in-human Clinical Trial of Oral ONC201 in Patients with Refractory Solid Tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28331050 DOI: 10.1158/1078-0432.Ccr-16-2658 |
0.518 |
|
| 2017 |
Leroy B, Ballinger ML, Baran-Marszak F, Bond GL, Braithwaite A, Concin N, Donehower LA, El-Deiry WS, Fenaux P, Gaidano G, Langerød A, Hellstrom-Lindberg E, Iggo R, Lehmann-Che J, Mai PL, et al. Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice. Cancer Research. PMID 28254861 DOI: 10.1158/0008-5472.Can-16-2179 |
0.364 |
|
| 2017 |
Teye EK, Sido A, Xin P, Finnberg NK, Gokare P, Kawasawa YI, Salzberg AC, Shimko S, Bayerl M, Ehmann WC, Claxton DF, Rybka WB, Drabik JJ, Wang HG, Abraham T, ... El-Deiry WS, et al. PIGN gene expression aberration is associated with genomic instability and leukemic progression in acute myeloid leukemia with myelodysplastic features. Oncotarget. PMID 28187452 DOI: 10.18632/Oncotarget.15136 |
0.33 |
|
| 2017 |
Weinberg BA, Lenz H, Arguello D, El-Deiry WS, Xiu J, Gatalica Z, Liu Z, Chen S, El Ghazaly H, Hwang JJ, Philip PA, Shields AF, Marshall J, Salem ME. Molecular characterization of squamous cell carcinoma of the anal canal (SCCA). Journal of Clinical Oncology. 35: 538-538. DOI: 10.1200/Jco.2017.35.4_Suppl.538 |
0.349 |
|
| 2017 |
Salem ME, Xiu J, Weinberg BA, El-Deiry WS, Weiner LM, Gatalica Z, Liu Z, El Ghazaly H, Xiao N, Hwang JJ, Philip PA, Shields AF, Lenz H, Marshall J. Characterization of tumor mutation burden (TMB) in gastrointestinal (GI) cancers. Journal of Clinical Oncology. 35: 530-530. DOI: 10.1200/Jco.2017.35.4_Suppl.530 |
0.395 |
|
| 2017 |
Marshall J, Lenz H, Xiu J, El-Deiry WS, Swensen J, El Ghazaly H, Gatalica Z, Hwang JJ, Philip PA, Shields AF, Salem ME. Molecular variances between rectal and left-sided colon cancers. Journal of Clinical Oncology. 35: 522-522. DOI: 10.1200/Jco.2017.35.4_Suppl.522 |
0.403 |
|
| 2017 |
Hyman DM, Laetsch TW, Kummar S, DuBois SG, Farago AF, Pappo AS, Demetri GD, El-Deiry WS, Lassen UN, Dowlati A, Brose MS, Boni V, Turpin B, Nagasubramanian R, Cruickshank S, et al. The efficacy of larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers. Journal of Clinical Oncology. 35: LBA2501-LBA2501. DOI: 10.1200/Jco.2017.35.18_Suppl.Lba2501 |
0.321 |
|
| 2017 |
Stein MN, Chan N, Silk AW, Malhotra J, Aisner J, Aiken R, Zloza A, El-Deiry WS, Newman J, Chesson C, Tarapore R, Allen JE, Oster W, Saunders T, Yu B, et al. Anticancer and immunostimulatory activity of the imipridone ONC201, a selective DRD2 antagonist, in advanced cancer patients. Journal of Clinical Oncology. 35: 2586-2586. DOI: 10.1200/Jco.2017.35.15_Suppl.2586 |
0.538 |
|
| 2017 |
Salem ME, Xiu J, Lenz H, Atkins MB, Philip PA, Hwang JJ, Gatalica Z, Xiao N, Gibney GT, El-Deiry WS, Tan AR, Kim ES, Shields AF, Raghavan D, Marshall J. Characterization of tumor mutation load (TML) in solid tumors. Journal of Clinical Oncology. 35: 11517-11517. DOI: 10.1200/Jco.2017.35.15_Suppl.11517 |
0.423 |
|
| 2017 |
Abbosh PH, Liu D, Johnson MH, El-Deiry WS, Plimack ER, Rosenberg JE, Allen EMV. Abstract B14: Neoantigen burden associates with chemoresponse in muscle-invasive bladder cancer patients receiving neoadjuvant chemotherapy Clinical Cancer Research. 23. DOI: 10.1158/1557-3265.Pmccavuln16-B14 |
0.401 |
|
| 2017 |
Finnberg NK, Abdulghani J, Ehya H, El-Deiry W. Abstract 5636: Targeting of NOXA overexpression in anaplastic thyroid cancer (ATC) Cancer Research. 77: 5636-5636. DOI: 10.1158/1538-7445.Am2017-5636 |
0.445 |
|
| 2017 |
Lulla AR, Einarson MB, Zhou Y, Dicker DT, El-Deiry WS. Abstract 5455: Novel miRNA-based therapeutic approach to selectively target mutant p53 in cancer Cancer Research. 77: 5455-5455. DOI: 10.1158/1538-7445.Am2017-5455 |
0.396 |
|
| 2017 |
Borrero LJH, Zhang S, Dicker DT, El-Deiry WS. Abstract 5178: CB002, a novel p53 pathway-restoring compound that induces apoptosis through the pro-apototic protein NOXA Cancer Research. 77: 5178-5178. DOI: 10.1158/1538-7445.Am2017-5178 |
0.544 |
|
| 2017 |
Zhao S, Dicker DT, El-Deiry WS. Abstract 4516: Dual inhibition of CDK1 and HSP90 destabilizes HIF1α and synergistically induces cancer cell death Cancer Research. 77: 4516-4516. DOI: 10.1158/1538-7445.Am2017-4516 |
0.473 |
|
| 2017 |
Prabhu VV, Madhukar N, Wagner J, Tarapore R, Garnett M, McDermott U, Benes C, Charter N, Deacon S, VanEngelenburg A, Elemento O, El-Deiry W, Stogniew M, Oster W, Allen J. Abstract 4147A: Potent anti-cancer activity of the imipridone ONC206: A selective dopamine D2-like receptor antagonist Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-4147A |
0.572 |
|
| 2017 |
Wagner J, Kline CL, Olson G, Nallaganchu B, Pottorf R, Prabhu V, Stogniew M, Allen J, El-Deiry W. Abstract 3245: Preclinical evaluation of the imipridone family of small molecules, including analogues of clinical-stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212 Cancer Research. 77: 3245-3245. DOI: 10.1158/1538-7445.Am2017-3245 |
0.59 |
|
| 2017 |
Kline CLB, Lulla A, Wagner J, Dicker D, Baumeister M, Oster S, El-Deiry W. Abstract 3213: Antagonism of D2-like dopamine receptors plays a role in Onc201’s anticancer effects Cancer Research. 77: 3213-3213. DOI: 10.1158/1538-7445.Am2017-3213 |
0.412 |
|
| 2017 |
Baumeister MD, Küçükkase OC, Prabhu VV, Dicker DT, Allen JE, El-Deiry WS. Abstract 3212: ONC201 shows efficacy in BRCA-deficient cancer cells and synergy with PARP inhibitors in glioblastoma, breast, prostate, and ovarian cancers Cancer Research. 77: 3212-3212. DOI: 10.1158/1538-7445.Am2017-3212 |
0.483 |
|
| 2017 |
Madhukar N, Prabhu VV, Dardenne E, Doherty F, VanEngelenburg A, Tarapore R, Garnett M, McDermott U, Benes C, Oster W, El-Deiry W, Stein M, Rickman D, Allen J, Elemento O. Abstract 2792: The small molecule imipridone ONC201 is active in tumor types with dysregulation of the DRD2 pathway Cancer Research. 77: 2792-2792. DOI: 10.1158/1538-7445.Am2017-2792 |
0.605 |
|
| 2017 |
Abbosh PH, Sikder RK, El-Deiry WS. Abstract 2356: Functional characterization ofCDKN1Aloss in bladder cancer and effects on cisplatin sensitivity Cancer Research. 77: 2356-2356. DOI: 10.1158/1538-7445.Am2017-2356 |
0.517 |
|
| 2017 |
Lulla AR, Einarson MB, Zhou Y, Slifker M, Dicker DT, El-Deiry WS. Abstract 2337: miR-6883 and family miRNAs induce G1-arrest in colon cancer cells by targeting CDK4/6 Cancer Research. 77: 2337-2337. DOI: 10.1158/1538-7445.Am2017-2337 |
0.309 |
|
| 2017 |
Zhang S, Zhou L, Dicker D, El-Deiry WS. Abstract 2156: NSC59984 induces mutant p53 degradation via activating ERK2 pathway-MDM2 axis Cancer Research. 77: 2156-2156. DOI: 10.1158/1538-7445.Am2017-2156 |
0.485 |
|
| 2017 |
Zhang S, Zhou L, El-Deiry WS. Abstract 2155: Small molecule NSC59984 suppresses cancer cell growth under hypoxia Cancer Research. 77: 2155-2155. DOI: 10.1158/1538-7445.Am2017-2155 |
0.507 |
|
| 2017 |
Tian X, Zhang S, Lulla A, El-Deiry wS. Abstract 2154: P53 pathway restoring compound P306 inhibits colorectal cancer growth Cancer Research. 77: 2154-2154. DOI: 10.1158/1538-7445.Am2017-2154 |
0.395 |
|
| 2017 |
Lev A, Lulla AR, Dicker DT, El-Deiry WS. Abstract 2102: ONC201 targets AR and AR-V7 signaling pathways, reduces PSA and synergizes with everolimus in castration resistant prostate cancer Cancer Research. 77: 2102-2102. DOI: 10.1158/1538-7445.Am2017-2102 |
0.371 |
|
| 2017 |
Zhang S, Wagner J, Zhou L, El-Deiry WS. Abstract 1892: Small molecule NSC59984 prevents cancer cell migration and invasion Cancer Research. 77: 1892-1892. DOI: 10.1158/1538-7445.Am2017-1892 |
0.373 |
|
| 2017 |
Deihimi S, Slifker M, Ross EA, El-Deiry WS. Abstract 1412: High EGFR somatic mutation frequency targeting the TK domain in colorectal cancer patients with microsatellite instability (MSI) Cancer Research. 77: 1412-1412. DOI: 10.1158/1538-7445.Am2017-1412 |
0.374 |
|
| 2017 |
Wagner J, Kline CL, Zhou L, Zloza A, Chesson C, Newman J, Kaufman H, Bertino J, Stein M, El-Deiry W. Abstract 124: Imipridone ONC201 promotes intra-tumoral accumulation of CD3+/NK+ cells that contribute to its anti-tumor efficacy Cancer Research. 77: 124-124. DOI: 10.1158/1538-7445.Am2017-124 |
0.458 |
|
| 2017 |
Wagner J, El-Deiry W. Abstract 1102: Anti-tumor effects of imipridone ONC201 in combination with anti-angiogenic agents significantly impact on colorectal cancer growthin vivo Cancer Research. 77: 1102-1102. DOI: 10.1158/1538-7445.Am2017-1102 |
0.431 |
|
| 2017 |
Lev A, Lulla AR, Wagner J, Dicker DT, El-Deiry WS. Abstract 1067: Anti-cancer efficacy of imipridones in pancreatic cancer: single agent ONC212 or combination of ONC201 with IGF1-R inhibition Cancer Research. 77: 1067-1067. DOI: 10.1158/1538-7445.Am2017-1067 |
0.441 |
|
| 2017 |
Prabhu VV, Madhukar N, Kline CLB, Tarapore RS, El-Deiry W, Elemento O, Rucker J, Doranz B, Doherty F, VanEngelenburg A, Durrant J, Benes C, Arrillaga-Romany I, Oster W, Allen JE. DDIS-08. THE SMALL MOLECULE IMIPRIDONE ONC201 IS ACTIVE IN GLIOBLASTOMA WITH DRD2 PATHWAY DYSREGULATION Neuro-Oncology. 19: vi60-vi60. DOI: 10.1093/Neuonc/Nox168.244 |
0.46 |
|
| 2016 |
El-Deiry WS. p21(WAF1) Mediates Cell-Cycle Inhibition, Relevant to Cancer Suppression and Therapy. Cancer Research. 76: 5189-91. PMID 27635040 DOI: 10.1158/0008-5472.Can-16-2055 |
0.472 |
|
| 2016 |
Allen JE, Kline CL, Prabhu VV, Wagner J, Ishizawa J, Madhukar N, Lev A, Baumeister M, Zhou L, Lulla A, Stogniew M, Schalop L, Benes C, Kaufman HL, Pottorf RS, ... ... El-Deiry WS, et al. Discovery and clinical introduction of first-in-class imipridone ONC201. Oncotarget. PMID 27602582 DOI: 10.18632/Oncotarget.11814 |
0.58 |
|
| 2016 |
Tan CR, Zhou L, El-Deiry WS. Circulating Tumor Cells Versus Circulating Tumor DNA in Colorectal Cancer: Pros and Cons. Current Colorectal Cancer Reports. 12: 151-161. PMID 27516729 DOI: 10.1007/S11888-016-0320-Y |
0.393 |
|
| 2016 |
Abdulghani J, Gokare P, Gallant JN, Dicker DT, Whitcomb T, Cooper TK, Liao J, Derr J, Liu J, Goldenberg D, Finnberg NK, El-Deiry WS. Sorafenib and quinacrine target anti-apoptotic protein Mcl-1: a poor prognostic marker in anaplastic thyroid cancer (ATC). Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27307592 DOI: 10.1158/1078-0432.Ccr-15-2792 |
0.419 |
|
| 2016 |
Kline CL, Van den Heuvel AP, Allen JE, Prabhu VV, Dicker DT, El-Deiry WS. ONC201 kills solid tumor cells by triggering an integrated stress response dependent on ATF4 activation by specific eIF2α kinases. Science Signaling. 9: ra18. PMID 26884600 DOI: 10.1126/Scisignal.Aac4374 |
0.628 |
|
| 2016 |
Allen JE, Crowder RN, El-Deiry WS. Correction: First-In-Class Small Molecule ONC201 Induces DR5 and Cell Death in Tumor but Not Normal Cells to Provide a Wide Therapeutic Index as an Anti-Cancer Agent. Plos One. 11: e0149365. PMID 26863230 DOI: 10.1371/journal.pone.0149365 |
0.534 |
|
| 2016 |
Klionsky DJ, Abdelmohsen K, Abe A, Abedin MJ, Abeliovich H, Acevedo Arozena A, Adachi H, Adams CM, Adams PD, Adeli K, Adhihetty PJ, Adler SG, Agam G, Agarwal R, Aghi MK, ... ... El-Deiry WS, et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy. 12: 1-222. PMID 26799652 DOI: 10.1080/15548627.2015.1100356 |
0.312 |
|
| 2016 |
Prabhu VV, Hong B, Allen JE, Zhang S, Lulla A, Dicker DT, El-Deiry WS. Small molecule prodigiosin restores p53 tumor suppressor activity in chemoresistant colorectal cancer stem cells via c-Jun-mediated ΔNp73 inhibition and p73 activation. Cancer Research. PMID 26759239 DOI: 10.1158/0008-5472.Can-14-2430 |
0.637 |
|
| 2016 |
Crowder RN, Dicker DT, El-Deiry WS. The Deubiquitinase Inhibitor PR-619 Sensitizes Normal Human Fibroblasts to Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL)-mediated Cell Death. The Journal of Biological Chemistry. 291: 5960-70. PMID 26757822 DOI: 10.1074/Jbc.M115.713545 |
0.513 |
|
| 2016 |
Finnberg NK, Gokare P, Navaraj A, Lang Kuhs KA, Cerniglia G, Yagita H, Takeda K, Motoyama N, El-Deiry WS. Agonists of the TRAIL Death Receptor DR5 Sensitize Intestinal Stem Cells to Chemotherapy-Induced Cell Death and Trigger Gastrointestinal Toxicity. Cancer Research. 76: 700-12. PMID 26609054 DOI: 10.1158/0008-5472.Can-15-2759 |
0.478 |
|
| 2016 |
Wagner J, Olson G, Nallaganchu BR, Pottorf R, Stogniew M, Schalop L, Oster W, Garnett M, McDermott U, Benes C, Tarapore R, Allen JE, El-Deiry WS. Structure-activity relationships (SAR) and mechanistic analysis of clinical-stage anti-cancer small molecule ONC201 analogues. Journal of Clinical Oncology. 34: e23161-e23161. DOI: 10.1200/Jco.2016.34.15_Suppl.E23161 |
0.591 |
|
| 2016 |
Lev A, Wagner J, Lulla AR, Dicker DT, El-Deiry WS. Preclinical efficacy of new investigational drug ONC201 and analogs ONC212 and ONC206 against patient-derived pancreatic cancer cell lines. Journal of Clinical Oncology. 34. DOI: 10.1200/Jco.2016.34.15_Suppl.E15752 |
0.436 |
|
| 2016 |
El-Deiry WS, Wagner J. Effect of combination of ONC201 and bevacizumab on colorectal cancer (CRC) growth and metastasis in vivo. Journal of Clinical Oncology. 34. DOI: 10.1200/Jco.2016.34.15_Suppl.E15155 |
0.401 |
|
| 2016 |
Baumeister MD, Wagner J, Prabhu VV, Kline CLB, Allen JE, Dicker DT, El-Deiry WS. Preclinical activity of new investigational drug ONC201 in triple-negative and non-triple negative and BRCA1-deficient breast cancer cells. Journal of Clinical Oncology. 34: e12564-e12564. DOI: 10.1200/Jco.2016.34.15_Suppl.E12564 |
0.61 |
|
| 2016 |
Salem ME, Marshall J, Feldman R, Pishvaian MJ, El-Deiry WS, Hwang JJ, Lou E, Wang H, Gatalica Z, Reddy SK, Shields AF, Philip PA. Comparative molecular analyses of pancreatic cancer (PC): KRAS wild type vs. KRAS mutant tumors and primary tumors vs. distant metastases. Journal of Clinical Oncology. 34: 4121-4121. DOI: 10.1200/Jco.2016.34.15_Suppl.4121 |
0.355 |
|
| 2016 |
Salem ME, Xiu J, Khan SA, Wang H, Smaglo BG, El-Deiry WS, Hwang JJ, Pishvaian MJ, Lou E, Shields AF, Philip PA, Gatalica Z, Reddy SK, Marshall J. Comparative molecular analyses of esophageal cancer: Adenocarcinoma vs. squamous cell carcinomas and impact on outcome. Journal of Clinical Oncology. 34: 4035-4035. DOI: 10.1200/Jco.2016.34.15_Suppl.4035 |
0.373 |
|
| 2016 |
Christiansen SA, Feldman R, Atkins MB, El-Deiry WS, Vanderwalde AM, Pishvaian MJ, Hwang JJ, Flaherty LE, Denlinger CS, Reddy SK, Marshall J, Salem ME. Comparative molecular analyses of BRAF-V600E mutant tumors: Colorectal cancers (CRC) vs. melanomas. Journal of Clinical Oncology. 34: 3598-3598. DOI: 10.1200/Jco.2016.34.15_Suppl.3598 |
0.327 |
|
| 2016 |
Marshall J, Xiu J, El-Deiry WS, Hwang JJ, Gatalica Z, Pishvaian MJ, Philip PA, Reddy SK, Shields AF, Salem ME. Comparative molecular analyses of colon versus rectal tumors. Journal of Clinical Oncology. 34: 3552-3552. DOI: 10.1200/Jco.2016.34.15_Suppl.3552 |
0.36 |
|
| 2016 |
Ramamurthy C, Shameem R, Forman A, Dolinsky JS, Speare V, McFarland RE, El-Deiry WS, Hall MJ, Daly MB, Goldstein LJ, Obeid E. Risk of HER2-positive breast cancer among germline CHEK2 mutation carriers with breast cancer. Journal of Clinical Oncology. 34: 1539-1539. DOI: 10.1200/Jco.2016.34.15_Suppl.1539 |
0.307 |
|
| 2016 |
El-Deiry WS, Xiu J, Obeid E, Mehra R, Astsaturov IA, Wagner J, Lev A, Baumeister M, Shields AF, Salem ME, Hwang JJ, Vijayvergia N, Denlinger CS, Dotan E, Borghaei H, et al. Tumor profiling of liver metastases (LM) from CRC, NSCLC, pancreatic (PC), breast (BC) and gastroesophageal (GE) tumors to reveal differences versus primary tumors including in cMET, MYC, CDK4, Her2, b-catenin and PD1. Journal of Clinical Oncology. 34: 11604-11604. DOI: 10.1200/Jco.2016.34.15_Suppl.11604 |
0.334 |
|
| 2016 |
Wagner J, Kline CLB, El-Deiry WS. Dose-intensified ONC201 to exert anti-metastatic efficacy and to promote intra-tumoral recruitment of NK-cells in mice. Journal of Clinical Oncology. 34: 11550-11550. DOI: 10.1200/Jco.2016.34.15_Suppl.11550 |
0.378 |
|
| 2016 |
Astsaturov IA, Ellis P, Swensen J, Arguello D, Reddy SK, Gatalica Z, El-Deiry WS. Fusion analysis of solid tumors to reveal novel rearrangements in breast carcinomas. Journal of Clinical Oncology. 34: 11504-11504. DOI: 10.1200/Jco.2016.34.15_Suppl.11504 |
0.371 |
|
| 2016 |
Prabhu VV, Tarapore RS, Garnett MJ, McDermott U, Benes CH, Wagner JM, El-Deiry WS, Stogniew M, Oster W, Allen JE. Potent Anti-Leukemic Effects of Small Molecule ONC212, a Member of the Imipridone Class of Anti-Cancer Compounds Blood. 128: 5133-5133. DOI: 10.1182/Blood.V128.22.5133.5133 |
0.586 |
|
| 2016 |
Prabhu VV, Lulla A, Kline CL, Van den Heuvel PJ, Talekar MK, Wagner JM, Tarapore RS, Dicker DT, Garnett MJ, McDermott U, Benes CH, Pu JJ, Claxton DF, Oster W, Allen JE, ... El-Deiry WS, et al. Single Agent and Combinatorial Efficacy of First-in-Class Small Molecule ONC201 in Acute Leukemia and Multiple Myeloma Blood. 128: 2759-2759. DOI: 10.1182/Blood.V128.22.2759.2759 |
0.624 |
|
| 2016 |
Gokare PR, Finnberg N, Dai J, El-Deiry W. Abstract PR03: P53 inhibits the expression of the pyrimidine catabolic gene Dihydropyrimidine dehydrogenase (DPYD) Molecular Cancer Research. 14. DOI: 10.1158/1557-3125.Metca15-Pr03 |
0.411 |
|
| 2016 |
Madhukar NS, Elemento O, Benes CH, Garnett MJ, Stein M, Bertino JR, Kaufman HL, Arrillaga-Romany I, Batchelor TT, Schalop L, Oster W, Stogniew M, Andreeff M, El-Deiry WS, Allen JE. Abstract LB-209: D2-like dopamine receptor antagonism by ONC201 identified by confluence of computational, receptor binding, and clinical studies Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Lb-209 |
0.527 |
|
| 2016 |
Matthew EM, Yang Z, Peri S, Vijayvergia N, Lulla A, Ross E, El-Deiry WS. Abstract LB-023: Plk2 loss occurs commonly in colorectal carcinomas but not in adenomas Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Lb-023 |
0.414 |
|
| 2016 |
Xiu J, Reddy S, El-Deiry WS. Abstract 4923: Expression of class III beta-tubulin (TUBB3) in 3580 colorectal cancers (CRCs) and correlation with clinico-pathological and molecular features Cancer Research. 76: 4923-4923. DOI: 10.1158/1538-7445.Am2016-4923 |
0.393 |
|
| 2016 |
Lev A, Wagner J, Dicker DT, Stogniew M, Allen JE, Schalop L, Oster W, Olson GL, El-Deiry WS. Abstract 4826: ONC212 exhibits increased cytotoxicity relative to ONC201 in a subset of human pancreatic cancer cell lines Cancer Research. 76: 4826-4826. DOI: 10.1158/1538-7445.Am2016-4826 |
0.615 |
|
| 2016 |
Lev A, Shagisultanova E, Deihimi S, Dicker DT, Xui J, El-Deiry WS. Abstract 4825: A rationale for treatment of colorectal cancer with mitomycin C and crizotinib Cancer Research. 76: 4825-4825. DOI: 10.1158/1538-7445.Am2016-4825 |
0.447 |
|
| 2016 |
Tian X, Zhang S, El-Deiry WS. Abstract 3830: Synthesis and anticancer activity of novel prodigiosin analogs Cancer Research. 76: 3830-3830. DOI: 10.1158/1538-7445.Am2016-3830 |
0.474 |
|
| 2016 |
Zhang S, Zhou L, Dicker D, El-Deiry WS. Abstract 3816: Reactive oxygen species and ERK2 phosphorylation are required for NSC59984 to induce mutant p53 protein degradation and restore p53 signaling Cancer Research. 76: 3816-3816. DOI: 10.1158/1538-7445.Am2016-3816 |
0.45 |
|
| 2016 |
Gokare PR, Finnberg N, Dai J, Murphy M, El-Deiry W. Abstract 3706: p53 represses pyrimidine catabolic gene dihydropyrimidine dehydrogenase (DPYD) expression following thymidylate synthase (TS) inhibition Cancer Research. 76: 3706-3706. DOI: 10.1158/1538-7445.Am2016-3706 |
0.476 |
|
| 2016 |
Wagner J, Olson G, Bhaskara NR, Pottorf RS, Mathew GJ, Benes CH, Tarapore R, Stogniew M, Schalop L, Oster W, Allen JE, El-Deiry WS. Abstract 349: Structure-activity relationships and mechanistic analysis of analogues of the clinical-stage anti-cancer small molecule ONC201 Cancer Research. 76: 349-349. DOI: 10.1158/1538-7445.Am2016-349 |
0.463 |
|
| 2016 |
Baumeister MD, Wagner J, Prabhu VV, Kline CL, Lim B, Allen JE, Dicker DT, El-Deiry WS. Abstract 3309: Novel small molecule ONC201 induces cell death and targets chemotherapy-resistant cancer stem-like cells in triple negative breast cancer Cancer Research. 76: 3309-3309. DOI: 10.1158/1538-7445.Am2016-3309 |
0.424 |
|
| 2016 |
Borrero LJH, Zhang S, Dicker D, El-Deiry W. Abstract 327: Anti-tumor effect and destabilization of R175H-mutant p53 by CB002, a p53-pathway restoring small molecule that stimulates autophagy Cancer Research. 76: 327-327. DOI: 10.1158/1538-7445.Am2016-327 |
0.519 |
|
| 2016 |
Wagner J, El-Deiry WS. Abstract 3087: Combination of ONC201 and bevacizumab significantly impacts colorectal cancer growth and metastasisin vivo Cancer Research. 76: 3087-3087. DOI: 10.1158/1538-7445.Am2016-3087 |
0.421 |
|
| 2016 |
Kline CLB, El-Deiry WS. Abstract 3014: ONC201 anti-cancer effects against solid tumors are mediated through eIF2α kinases HRI and PKR but are PERK-independent Cancer Research. 76: 3014-3014. DOI: 10.1158/1538-7445.Am2016-3014 |
0.464 |
|
| 2016 |
Baumeister MD, Wagner J, Prabhu VV, Kline CL, Lim B, Allen JE, Dicker DT, El-Deiry WS. Abstract 3012: ONC201 induces cell death in triple negative, BRCA1-deficient and non-triple negative breast cancer cells Cancer Research. 76: 3012-3012. DOI: 10.1158/1538-7445.Am2016-3012 |
0.39 |
|
| 2016 |
Wagner J, Kline CLB, Baumeister M, El-Deiry WS. Abstract 3000: Intra-tumoral accumulation of NK1.1/CD3+ cells and anti-metastasis effects of dose-intensified ONC201 in tumor-bearing mice Cancer Research. 76: 3000-3000. DOI: 10.1158/1538-7445.Am2016-3000 |
0.401 |
|
| 2016 |
Zhang J, Zhou L, Zhao S, Dicker D, El-Deiry WS. Abstract 2840: CDK4/6 inhibitor PD-0332991 (palbociclib) promotes cell death and synergizes with CPT-11 in colorectal cancer under hypoxiain vitro Cancer Research. 76: 2840-2840. DOI: 10.1158/1538-7445.Am2016-2840 |
0.474 |
|
| 2016 |
Zhao S, Dicker DT, El-Deiry WS. Abstract 2798: Enhanced HIF1α inhibition through dual inhibition of CDK and HSP90 Cancer Research. 76: 2798-2798. DOI: 10.1158/1538-7445.Am2016-2798 |
0.438 |
|
| 2016 |
Deihimi S, Lev A, Shagisultanova E, Xiu J, Slifker M, Xu Q, Dicker DT, Ross EA, Dunbrack R, El-Deiry WS. Abstract 2751: Frequent BRCA2 somatic mutations in colorectal cancer patients with microsatellite instability (MSI) Cancer Research. 76: 2751-2751. DOI: 10.1158/1538-7445.Am2016-2751 |
0.338 |
|
| 2016 |
Prabhu VV, Allen JE, Zhao D, Lulla AR, Kline CLB, Heuvel APJvd, Lev A, Batchelor TT, Dicker DT, Chi AS, El-Deiry WS. Abstract 2497: ONC201 targets cancer stem cells in colorectal, prostate and glioblastoma multiforme tumors via modulation of stem cell-related gene expression Cancer Research. 76: 2497-2497. DOI: 10.1158/1538-7445.Am2016-2497 |
0.612 |
|
| 2016 |
Lev A, Lulla AR, Dicker DT, El-Deiry WS. Abstract 1825: ONC201 induces cell death in androgen receptor positive prostate cancer cells and shows synergistic effect with anti-prostate cancer drugs Cancer Research. 76: 1825-1825. DOI: 10.1158/1538-7445.Am2016-1825 |
0.416 |
|
| 2015 |
Matthew EM, Zhou L, Yang Z, Dicker DT, Holder SL, Lim B, Harouaka R, Zheng SY, Drabick JJ, Lamparella NE, Truica CI, El-Deiry WS. A multiplexed marker-based algorithm for diagnosis of carcinoma of unknown primary using circulating tumor cells. Oncotarget. PMID 26695546 DOI: 10.18632/Oncotarget.6657 |
0.362 |
|
| 2015 |
Allen JE, Crowder R, El-Deiry WS. First-In-Class Small Molecule ONC201 Induces DR5 and Cell Death in Tumor but Not Normal Cells to Provide a Wide Therapeutic Index as an Anti-Cancer Agent. Plos One. 10: e0143082. PMID 26580220 DOI: 10.1371/Journal.Pone.0143082 |
0.58 |
|
| 2015 |
Marks EI, Tan C, Zhang J, Zhou L, Yang Z, Scicchitano A, El-Deiry WS. Regorafenib with a fluoropyrimidine for metastatic colorectal cancer after progression on multiple 5-FU-containing combination therapies and regorafenib monotherapy. Cancer Biology & Therapy. 0. PMID 26561209 DOI: 10.1080/15384047.2015.1113355 |
0.402 |
|
| 2015 |
El-Deiry WS, Vijayvergia N, Xiu J, Scicchitano A, Lim B, Yee NS, Harvey HA, Gatalica Z, Reddy S. Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites. Cancer Biology & Therapy. 0. PMID 26553611 DOI: 10.1080/15384047.2015.1113356 |
0.402 |
|
| 2015 |
Finnberg N, Gokare P, El-Deiry WS. Novel and Emerging Targeted Therapies of Colorectal Cancer. Current Clinical Pharmacology. 10: 279-98. PMID 26548905 DOI: 10.2174/1574884710666151020095911 |
0.36 |
|
| 2015 |
Zhang S, Zhou L, Hong B, van den Heuvel AP, Prabhu VV, Warfel NA, Kline CL, Dicker DT, Kopelovich L, El-Deiry WS. Small-Molecule NSC59984 Restores p53 Pathway Signaling and Antitumor Effects against Colorectal Cancer via p73 Activation and Degradation of Mutant p53. Cancer Research. 75: 3842-52. PMID 26294215 DOI: 10.1158/0008-5472.Can-13-1079 |
0.496 |
|
| 2015 |
Talekar MK, Allen JE, Dicker DT, El-Deiry WS. ONC201 induces cell death in pediatric non-Hodgkin's lymphoma cells. Cell Cycle (Georgetown, Tex.). 1-7. PMID 26030065 DOI: 10.1080/15384101.2015.1054086 |
0.631 |
|
| 2015 |
Lim B, Allen JE, Prabhu VV, Talekar MK, Finnberg NK, El-Deiry WS. Targeting TRAIL in the treatment of cancer: new developments. Expert Opinion On Therapeutic Targets. 1-15. PMID 26004811 DOI: 10.1517/14728222.2015.1049838 |
0.603 |
|
| 2015 |
Allen JE, Krigsfeld G, Patel L, Mayes PA, Dicker DT, Wu GS, El-Deiry WS. Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway. Molecular Cancer. 14: 99. PMID 25927855 DOI: 10.1186/S12943-015-0346-9 |
0.703 |
|
| 2015 |
Li P, Mao Z, Peng Z, Zhou L, Chen Y, Huang PH, Truica CI, Drabick JJ, El-Deiry WS, Dao M, Suresh S, Huang TJ. Acoustic separation of circulating tumor cells. Proceedings of the National Academy of Sciences of the United States of America. 112: 4970-5. PMID 25848039 DOI: 10.1073/Pnas.1504484112 |
0.393 |
|
| 2015 |
Kaifi JT, Kunkel M, Das A, Harouaka RA, Dicker DT, Li G, Zhu J, Clawson GA, Yang Z, Reed MF, Gusani NJ, Kimchi ET, Staveley-O'Carroll KF, Zheng SY, El-Deiry WS. Circulating tumor cell isolation during resection of colorectal cancer lung and liver metastases: a prospective trial with different detection techniques. Cancer Biology & Therapy. 16: 699-708. PMID 25807199 DOI: 10.1080/15384047.2015.1030556 |
0.369 |
|
| 2015 |
Das A, Kunkel M, Joudeh J, Dicker DT, Scicchitano A, Allen JE, Sarwani N, Yang Z, Kaifi J, Zhu J, Liao J, El-Deiry WS. Clinico-pathological correlation of serial measurement of circulating tumor cells in 24 metastatic colorectal cancer patients receiving chemotherapy reveals interpatient heterogeneity correlated with CEA levels but independent of KRAS and BRAF mutation. Cancer Biology & Therapy. 16: 709-13. PMID 25806877 DOI: 10.1080/15384047.2015.1030555 |
0.56 |
|
| 2015 |
Kaifi JT, Kunkel M, Dicker DT, Joude J, Allen JE, Das A, Zhu J, Yang Z, Sarwani NE, Li G, Staveley-O'Carroll KF, El-Deiry WS. Circulating tumor cell levels are elevated in colorectal cancer patients with high tumor burden in the liver. Cancer Biology & Therapy. 16: 690-8. PMID 25785486 DOI: 10.1080/15384047.2015.1026508 |
0.559 |
|
| 2015 |
Prabhu VV, El-Deiry WS. 4th international conference on tumor progression and therapeutic resistance: meeting report. Cancer Biology & Therapy. 16: 363-76. PMID 25782066 DOI: 10.1080/15384047.2015.1004928 |
0.377 |
|
| 2015 |
Prabhu VV, Allen JE, Dicker DT, El-Deiry WS. Small-Molecule ONC201/TIC10 Targets Chemotherapy-Resistant Colorectal Cancer Stem-like Cells in an Akt/Foxo3a/TRAIL-Dependent Manner. Cancer Research. 75: 1423-32. PMID 25712124 DOI: 10.1158/0008-5472.Can-13-3451 |
0.635 |
|
| 2015 |
McKee CM, Ding Y, Zhou J, Li C, Huang L, Xin X, He J, Allen JE, El-Deiry WS, Cao Y, Muschel RJ, Xu D. Protease nexin 1 induces apoptosis of prostate tumor cells through inhibition of X-chromosome-linked inhibitor of apoptosis protein. Oncotarget. 6: 3784-96. PMID 25686839 DOI: 10.18632/Oncotarget.2921 |
0.603 |
|
| 2015 |
Allen JE, Prabhu VV, Talekar M, van den Heuvel AP, Lim B, Dicker DT, Fritz JL, Beck A, El-Deiry WS. Genetic and Pharmacological Screens Converge in Identifying FLIP, BCL2, and IAP Proteins as Key Regulators of Sensitivity to the TRAIL-Inducing Anticancer Agent ONC201/TIC10. Cancer Research. 75: 1668-74. PMID 25681273 DOI: 10.1158/0008-5472.Can-14-2356 |
0.597 |
|
| 2015 |
Ma Y, Hao S, Wang S, Zhao Y, Lim B, Lei M, Spector DJ, El-Deiry WS, Zheng SY, Zhu J. A Combinatory Strategy for Detection of Live CTCs Using Microfiltration and a New Telomerase-Selective Adenovirus. Molecular Cancer Therapeutics. 14: 835-43. PMID 25589497 DOI: 10.1158/1535-7163 |
0.405 |
|
| 2015 |
Galluzzi L, Bravo-San Pedro JM, Vitale I, Aaronson SA, Abrams JM, Adam D, Alnemri ES, Altucci L, Andrews D, Annicchiarico-Petruzzelli M, Baehrecke EH, Bazan NG, Bertrand MJ, Bianchi K, Blagosklonny MV, ... ... El-Deiry WS, et al. Essential versus accessory aspects of cell death: recommendations of the NCCD 2015. Cell Death and Differentiation. 22: 58-73. PMID 25236395 DOI: 10.1038/Cdd.2014.137 |
0.597 |
|
| 2015 |
Gatalica Z, Vijayvergia N, Vranic S, Xiu J, Reddy SK, Snyder CL, Lynch HT, El-Deiry WS. Therapeutic biomarker differences between MSI-H and MSS colorectal cancers. Journal of Clinical Oncology. 33: 3597-3597. DOI: 10.1200/Jco.2015.33.15_Suppl.3597 |
0.306 |
|
| 2015 |
Lim B, Dicker DT, Kline LC, El-Deiry WS. Abstract P6-11-08: Exploring the best therapeutic partner of triple negative breast cancers: Using different characteristics/dependent pathways of triple negative breast cancer cell lines based on subgroups Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P6-11-08 |
0.447 |
|
| 2015 |
Kline CL, Heuvel Pvd, Allen JE, Dicker DT, El-Deiry WS. Abstract 674: Early integrated stress response induction of ATF4 is required for the anticancer effects of the dual Akt/ERK inhibitor and TRAIL pathway inducer ONC201/TIC10 Cancer Research. 75: 674-674. DOI: 10.1158/1538-7445.Am2015-674 |
0.629 |
|
| 2015 |
Talekar MK, Dicker D, Allen J, El-Deiry W. Abstract 5387: ONC201/TIC10 is effective as a monoagent and synergizes with chemotherapy to induce cell death in non-Hodgkin's lymphoma Cancer Research. 75: 5387-5387. DOI: 10.1158/1538-7445.Am2015-5387 |
0.635 |
|
| 2015 |
Wagner J, Kline CL, Pottorf RS, Nallaganchu BR, Olson GL, Dicker DT, Allen JE, El-Deiry WS. Abstract 4499: Cytotoxicity, biochemical activity, and structural analysis of ONC201 and comparisons to a biologically inactive isomer Cancer Research. 75: 4499-4499. DOI: 10.1158/1538-7445.Am2015-4499 |
0.522 |
|
| 2015 |
Allen JE, El-Deiry WS. Abstract 4479: ONC201 is non-toxic at efficacious doses in vitro and in vivo Cancer Research. 75: 4479-4479. DOI: 10.1158/1538-7445.Am2015-4479 |
0.56 |
|
| 2015 |
Allen JE, Ishizawa J, El-Deiry WS, Andreeff M, Garnett M, Benes C. Abstract 4475: In vitro efficacy profiling of ONC201 in cancer cells reveals sensitivity pattern that is consistent with ER stress response Cancer Research. 75: 4475-4475. DOI: 10.1158/1538-7445.Am2015-4475 |
0.588 |
|
| 2015 |
Prabhu VV, Allen JE, Dicker DT, El-Deiry WS. Abstract 4241: ONC201/TIC10 targets colorectal cancer stem cells and bulk tumor cells via an Akt-Foxo3a-TRAIL-dependent mechanism Cancer Research. 75: 4241-4241. DOI: 10.1158/1538-7445.Am2015-4241 |
0.641 |
|
| 2015 |
Zhou L, Matthew EM, Dicker DT, El-Deiry WS. Abstract 382: Identification and characterization of circulating tumor cells with multiplexed Quantum Dot conjugated antibodies Cancer Research. 75: 382-382. DOI: 10.1158/1538-7445.Am2015-382 |
0.41 |
|
| 2015 |
Wang W, Dicker DT, Claxton DF, Wang H, El-Deiry WS. Abstract 3486: Synergistic effect of quinacrine in combination with decitabine for the treatment of acute myeloid leukemia cellsin vitro: implication for treatment of AML in the elderly Cancer Research. 75: 3486-3486. DOI: 10.1158/1538-7445.Am2015-3486 |
0.528 |
|
| 2015 |
Kline CL, Lulla AR, Dicker D, Allen JE, El-Deiry W. Abstract 2942: TRAIL pathway inducer ONC201/TIC10 primes multiple myeloma cells (MM) for apoptosis by downregulating X-linked inhibitor of apoptosis Cancer Research. 75: 2942-2942. DOI: 10.1158/1538-7445.Am2015-2942 |
0.6 |
|
| 2015 |
Finnberg NK, Gokare P, Navaraj A, Kuhs KAL, Cerniglia G, Yagita H, Takeda K, Motoyama N, El-Deiry WS. Abstract 2926: DR5-targeting sensitizes Lgr5+ stem cells to p53 and Chk2-dependent chemotherapy-induced cell death and produces dose-limiting gastrointestinal toxicity (GIT) Cancer Research. 75: 2926-2926. DOI: 10.1158/1538-7445.Am2015-2926 |
0.422 |
|
| 2015 |
Borrero LJH, Zhao S, Dicker DT, El-Deiry W. Abstract 2643: Small molecule identification for the restoration of p53 pathway through p73 and by degradation of mutant p53 Cancer Research. 75: 2643-2643. DOI: 10.1158/1538-7445.Am2015-2643 |
0.489 |
|
| 2015 |
Zhang S, Zhou L, Dicker DT, EL-Deiry WS. Abstract 2640: Small molecule compound NCI-8 induces ERK2-dependent mutant-p53 protein degradation Cancer Research. 75: 2640-2640. DOI: 10.1158/1538-7445.Am2015-2640 |
0.333 |
|
| 2015 |
Abdulghani J, Gallant J, Gokare P, Cooper T, Whitcomb T, Liao J, Liu J, Goldenberg D, Finnberg NK, El-Deiry WS. Abstract 2527: The drug combination sorafenib and quinacrine targets the expression of Mcl-1 - an anti-apoptotic protein and candidate prognostic factor in Anaplastic Thyroid Cancer (ATC) Cancer Research. 75: 2527-2527. DOI: 10.1158/1538-7445.Am2015-2527 |
0.383 |
|
| 2015 |
Prabhu VV, Zhang S, Hong B, Allen JE, Lulla A, Dicker DT, El-Deiry WS. Abstract 1215: Small molecule Prodigiosin-mediated p53 pathway restoration and inhibition of self-renewal in colorectal cancer involves c-Jun-mediated ΔNp73 inhibition and p73 activation Cancer Research. 75: 1215-1215. DOI: 10.1158/1538-7445.Am2015-1215 |
0.636 |
|
| 2015 |
Baumeister MD, Wagner J, Kline CLB, Allen JE, Dicker DT, El-Deiry WS. Abstract LB-A16: Novel Small Molecule ONC201 Induces Cell Death in Triple Negative and Non-triple Negative Breast Cancer Cells Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-Lb-A16 |
0.612 |
|
| 2014 |
Wagner J, Kline CL, Pottorf RS, Nallaganchu BR, Olson GL, Dicker DT, Allen JE, El-Deiry WS. The angular structure of ONC201, a TRAIL pathway-inducing compound, determines its potent anti-cancer activity. Oncotarget. 5: 12728-37. PMID 25587031 DOI: 10.18632/Oncotarget.2890 |
0.508 |
|
| 2014 |
Patel AS, Allen JE, Dicker DT, Sheehan JM, Glantz MJ, El-Deiry WS. Detection of circulating tumor cells in the cerebrospinal fluid of a patient with a solitary metastasis from breast cancer: A case report. Oncology Letters. 7: 2110-2112. PMID 24932298 DOI: 10.3892/Ol.2014.1993 |
0.523 |
|
| 2014 |
Condamine T, Kumar V, Ramachandran IR, Youn JI, Celis E, Finnberg N, El-Deiry WS, Winograd R, Vonderheide RH, English NR, Knight SC, Yagita H, McCaffrey JC, Antonia S, Hockstein N, et al. ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R-mediated apoptosis. The Journal of Clinical Investigation. 124: 2626-39. PMID 24789911 DOI: 10.1172/Jci74056 |
0.447 |
|
| 2014 |
Warfel NA, El-Deiry WS. HIF-1 signaling in drug resistance to chemotherapy Current Medicinal Chemistry. 21: 3021-3028. PMID 24735366 |
0.303 |
|
| 2014 |
Allen JE, Patel AS, Prabhu VV, Dicker DT, Sheehan JM, Glantz MJ, El-Deiry WS. COX-2 drives metastatic breast cells from brain lesions into the cerebrospinal fluid and systemic circulation. Cancer Research. 74: 2385-90. PMID 24614081 DOI: 10.1158/0008-5472.Can-13-2660 |
0.544 |
|
| 2014 |
Zhang L, Ren X, Cheng Y, Liu X, Allen JE, Zhang Y, Yuan Y, Huang SY, Yang W, Berg A, Webb BS, Connor J, Liu CG, Lu Z, El-Deiry WS, et al. The NFκB inhibitor, SN50, induces differentiation of glioma stem cells and suppresses their oncogenic phenotype. Cancer Biology & Therapy. 15: 602-11. PMID 24557012 DOI: 10.4161/Cbt.28158 |
0.546 |
|
| 2014 |
Li C, Chacko AM, Hu J, Hasegawa K, Swails J, Grasso L, El-Deiry WS, Nicolaides N, Muzykantov VR, Divgi CR, Coukos G. Antibody-based tumor vascular theranostics targeting endosialin/TEM1 in a new mouse tumor vascular model. Cancer Biology & Therapy. 15: 443-51. PMID 24553243 DOI: 10.4161/Cbt.27825 |
0.337 |
|
| 2014 |
Hong B, van den Heuvel AP, Prabhu VV, Zhang S, El-Deiry WS. Targeting tumor suppressor p53 for cancer therapy: strategies, challenges and opportunities. Current Drug Targets. 15: 80-9. PMID 24387333 DOI: 10.2174/1389450114666140106101412 |
0.448 |
|
| 2014 |
Allen JE, Saroya BS, Kunkel M, Dicker DT, Das A, Peters KL, Joudeh J, Zhu J, El-Deiry WS. Apoptotic circulating tumor cells (CTCs) in the peripheral blood of metastatic colorectal cancer patients are associated with liver metastasis but not CTCs. Oncotarget. 5: 1753-60. PMID 24334302 DOI: 10.18632/Oncotarget.1524 |
0.528 |
|
| 2014 |
Hong B, Prabhu VV, Zhang S, van den Heuvel AP, Dicker DT, Kopelovich L, El-Deiry WS. Prodigiosin rescues deficient p53 signaling and antitumor effects via upregulating p73 and disrupting its interaction with mutant p53. Cancer Research. 74: 1153-65. PMID 24247721 DOI: 10.1158/0008-5472.Can-13-0955 |
0.454 |
|
| 2014 |
Harouaka RA, Zhou MD, Yeh YT, Khan WJ, Das A, Liu X, Christ CC, Dicker DT, Baney TS, Kaifi JT, Belani CP, Truica CI, El-Deiry WS, Allerton JP, Zheng SY. Flexible micro spring array device for high-throughput enrichment of viable circulating tumor cells. Clinical Chemistry. 60: 323-33. PMID 24132944 DOI: 10.1373/Clinchem.2013.206805 |
0.41 |
|
| 2014 |
El-Deiry WS, Xiu J, Lim B, Scicchitano A, Feeley E, Harvey HA, Yee NS. Molecular profiling of 6,892 colorectal cancer patients to identify potential treatment options. Journal of Clinical Oncology. 32: 3637-3637. DOI: 10.1200/Jco.2014.32.15_Suppl.3637 |
0.352 |
|
| 2014 |
Talekar MK, Allen J, Dicker DT, El-Deiry WS. ONC201/TIC10 Is Effective As a Monoagent and Synergizes with Chemotherapy to Induce Cell Death in Non-Hodgkin Lymphoma Blood. 124: 5491-5491. DOI: 10.1182/Blood.V124.21.5491.5491 |
0.481 |
|
| 2014 |
Wang W, Lulla AR, Hernandez-Borrero LJ, Dicker DT, Teye EK, Talekar MK, Dolloff NG, Pu JJ, El-Deiry WS. Synergistic Effect of Quinacrine with Chemotherapeutics or TRAIL in Hematopoietic Malignant Cells Blood. 124: 5239-5239. DOI: 10.1182/Blood.V124.21.5239.5239 |
0.561 |
|
| 2014 |
Prabhu VV, Lulla AR, Wagner JM, Hernandez-Borrero LJ, Talekar MK, Kline CL, Dicker DT, Barth BM, Pu JJ, Claxton DF, Allen JE, El-Deiry WS. Small Molecule ONC201/TIC10 Induces Caspase-Dependent Apoptosis in Acute Lymphoblastic Leukemia Cells Via Modulation of Bcl-2 and IAP Family Proteins Blood. 124: 5237-5237. DOI: 10.1182/Blood.V124.21.5237.5237 |
0.628 |
|
| 2014 |
Wagner JM, Prabhu VV, Kline LL, Lulla AR, Hernandez-Borrero LJ, Pu JJ, Dicker DT, Barth BM, Claxton DF, Allen JE, El-Deiry WS. Screen of Small Molecule ONC201/TIC10 Identifies Single Agent Activity and Combinatorial Efficacy with Bortezomib, Rituximab or Dexamethasone in Killing of Acute Lymphoblastic Leukemia Cells Blood. 124: 5233-5233. DOI: 10.1182/Blood.V124.21.5233.5233 |
0.584 |
|
| 2014 |
Lulla AR, Kline CLB, Hernandez-Borrero LJ, Prabhu VV, Wagner JM, Dicker DT, Dolloff NG, Barth BM, Pu JJ, Claxton DF, Allen JE, El-Deiry WS. Caspase-Dependent Anti-Tumor Effects of ONC201/TIC10 on Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM) Blood. 124: 5224-5224. DOI: 10.1182/Blood.V124.21.5224.5224 |
0.624 |
|
| 2014 |
Prabhu VV, Ishizawa J, Zhao D, Allen JE, Batchelor TT, Chi AS, Andreeff M, El-Deiry WS. ONC201 Depletes Cancer Stem Cells in Refractory Cancer Patient Samples Blood. 124: 5219-5219. DOI: 10.1182/Blood.V124.21.5219.5219 |
0.592 |
|
| 2014 |
Allen JE, Ishizawa J, El-Deiry WS, Andreeff M. ONC201 Possesses a Benign Safety Profile at Highly Efficacious Doses in Normal Human Cells and Animal Toxicology Studies Blood. 124: 4812-4812. DOI: 10.1182/Blood.V124.21.4812.4812 |
0.583 |
|
| 2014 |
Matthew EM, Zhou L, Lim B, Lamparella NE, Dicker DT, Gallant J, Joshi M, Holder SL, Harouaka R, Zheng S, Drabick JJ, Truica CI, Yang Z, El-Deiry WS. Abstract 4822: Immunophenotyping circulating tumor cells in patients with unknown primary Cancer Research. 74: 4822-4822. DOI: 10.1158/1538-7445.Am2014-4822 |
0.413 |
|
| 2014 |
Prabhu VV, Hong B, Allen JE, Zhang S, Dicker DT, El-Deiry WS. Abstract 202: p53 pathway restoring small molecule Prodigiosin targets chemotherapy-resistant colorectal cancer stem cells in vitro and in vivo via p73 activation Cancer Research. 74: 202-202. DOI: 10.1158/1538-7445.Am2014-202 |
0.655 |
|
| 2014 |
Zhang S, Zhou L, Kline CLB, Dicker DT, El-Deiry WS. Abstract 1802: Small molecule compound NCI-8 induces mutant p53 degradation via inhibition of the MDM2-Hsp90 axis Cancer Research. 74: 1802-1802. DOI: 10.1158/1538-7445.Am2014-1802 |
0.454 |
|
| 2014 |
Kaifi J, Das A, Harouka R, Kunkel M, Zhu J, Dicker D, Kimchi E, Staveley-O'Carroll K, Gusani N, Reed M, Zheng S, El-Deiry W. Circulating Tumor Cells are Shed During Resection of Colorectal Cancer Liver and Lung Metastases Journal of Surgical Research. 186: 505. DOI: 10.1016/J.Jss.2013.11.211 |
0.363 |
|
| 2013 |
Xu HN, Feng M, Moon L, Dolloff N, El-Deiry W, Li LZ. REDOX IMAGING OF THE p53-DEPENDENT MITOCHONDRIAL REDOX STATE IN COLON CANCER EX VIVO. Journal of Innovative Optical Health Sciences. 6. PMID 26207147 DOI: 10.1142/S1793545813500168 |
0.383 |
|
| 2013 |
Kline CL, El-Deiry WS. Personalizing colon cancer therapeutics: targeting old and new mechanisms of action. Pharmaceuticals (Basel, Switzerland). 6: 988-1038. PMID 24276379 DOI: 10.3390/Ph6080988 |
0.343 |
|
| 2013 |
Warfel NA, Dolloff NG, Dicker DT, Malysz J, El-Deiry WS. CDK1 stabilizes HIF-1α via direct phosphorylation of Ser668 to promote tumor growth. Cell Cycle (Georgetown, Tex.). 12: 3689-701. PMID 24189531 DOI: 10.4161/Cc.26930 |
0.361 |
|
| 2013 |
Kaifi JT, Kunkel M, Zhu J, Dicker DT, Gusani N, Yang Z, Sarwani NE, Li G, Kimchi ET, Staveley-O'Carroll KF, El-Deiry WS. Circulating tumor cells are associated with diffuse spread in stage IV colorectal cancer patients. Cancer Biology & Therapy. 14: 1174-81. PMID 24153154 DOI: 10.4161/Cbt.26884 |
0.387 |
|
| 2013 |
Ide T, Brown-Endres L, Chu K, Ongusaha PP, Ohtsuka T, El-Deiry WS, Aaronson SA, Lee SW. Retraction notice to: GAMT, a p53-inducible modulator of apoptosis, is critical for the adaptive response to nutrient stress [Molecular Cell 36, November 13 379-392 (2009)] Molecular Cell. 51. PMID 24137726 DOI: 10.1016/J.Molcel.2013.08.005 |
0.394 |
|
| 2013 |
Abdulghani J, Allen JE, Dicker DT, Liu YY, Goldenberg D, Smith CD, Humphreys R, El-Deiry WS. Sorafenib sensitizes solid tumors to Apo2L/TRAIL and Apo2L/TRAIL receptor agonist antibodies by the Jak2-Stat3-Mcl1 axis. Plos One. 8: e75414. PMID 24086526 DOI: 10.1371/Journal.Pone.0075414 |
0.578 |
|
| 2013 |
El-Deiry WS. Investing in biomedical research is important. Cancer Biology & Therapy. 14: 869-70. PMID 24064471 DOI: 10.4161/Cbt.26551 |
0.306 |
|
| 2013 |
Lamparella NE, Saroya BS, Yang Z, Sarwani NE, El-Deiry WS. Contradictory KRAS mutation test results in a patient with metastatic colon cancer: a clinical dilemma in the era of personalized medicine. Cancer Biology & Therapy. 14: 699-702. PMID 23792572 DOI: 10.4161/Cbt.25095 |
0.386 |
|
| 2013 |
Al-Marrawi MY, Saroya BS, Brennan MC, Yang Z, Dykes TM, El-Deiry WS. Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer. Cancer Biology & Therapy. 14: 703-10. PMID 23792568 DOI: 10.4161/Cbt.25191 |
0.369 |
|
| 2013 |
Lim B, Scicchitano A, Beachler C, Gusani N, Sarwani N, Yang Z, Staveley-O'Carroll K, Ashkenazi A, Portera C, El-Deiry WS. FOLFIRI plus dulanermin (rhApo2L/TRAIL) in a patient with BRAF-mutant metastatic colon cancer. Cancer Biology & Therapy. 14: 711-9. PMID 23792567 DOI: 10.4161/Cbt.25310 |
0.383 |
|
| 2013 |
Gallant JN, Matthew EM, Cheng H, Harouaka R, Lamparella NE, Kunkel M, Yang Z, Harvey HA, Cream LV, Kumar SM, Robertson GP, Zheng S, Drabick JJ, Truica CI, El-Deiry WS. Predicting therapy response in live tumor cells isolated with the flexible micro spring array device. Cell Cycle (Georgetown, Tex.). 12: 2132-43. PMID 23759587 DOI: 10.4161/Cc.25165 |
0.379 |
|
| 2013 |
Allen JE, Gallant JN, Dicker DT, Amin S, Irby RB, Sharma AK, El-Deiry WS. The Akt inhibitor ISC-4 synergizes with cetuximab in 5-FU-resistant colon cancer. Plos One. 8: e59380. PMID 23555026 DOI: 10.1371/Journal.Pone.0059380 |
0.623 |
|
| 2013 |
Allen JE, El-Deiry WS. Calcein-effluxing human colon cancer cells are enriched for self-renewal capacity and depend on β-catenin. Oncotarget. 4: 184-91. PMID 23468473 DOI: 10.18632/Oncotarget.883 |
0.598 |
|
| 2013 |
El-Deiry WS. Impact of genetic targets on cancer therapy. Forward. Advances in Experimental Medicine and Biology. 779: v-vi. PMID 23461003 DOI: 10.1007/978-1-4614-6176-0 |
0.347 |
|
| 2013 |
Allen JE, Krigsfeld G, Mayes PA, Patel L, Dicker DT, Patel AS, Dolloff NG, Messaris E, Scata KA, Wang W, Zhou JY, Wu GS, El-Deiry WS. Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects. Science Translational Medicine. 5: 171ra17. PMID 23390247 DOI: 10.1126/Scitranslmed.3004828 |
0.739 |
|
| 2013 |
Joudeh J, Allen JE, Das A, Prabhu V, Farbaniec M, Adler J, El-Deiry WS. Novel antineoplastics targeting genetic changes in colorectal cancer. Advances in Experimental Medicine and Biology. 779: 1-34. PMID 23288633 DOI: 10.1007/978-1-4614-6176-0_1 |
0.567 |
|
| 2013 |
Warfel NA, El-Deiry WS. p21WAF1 and tumourigenesis: 20 years after. Current Opinion in Oncology. 25: 52-8. PMID 23159848 DOI: 10.1097/Cco.0B013E32835B639E |
0.301 |
|
| 2013 |
El-Deiry WS. Are we losing the war on cancer? Cancer Biology & Therapy. 14: 1189-1190. DOI: 10.4161/Cbt.27394 |
0.355 |
|
| 2013 |
El-Deiry WS. Welcoming paul dent as assistant editor-in-chief of cancer biology & therapy Cancer Biology and Therapy. 14: 773. DOI: 10.4161/Cbt.26121 |
0.358 |
|
| 2013 |
Allen JE, Gallant J, Dicker DT, Amin S, Irby RB, Sharma AK, El-Deiry WS. Correction: The Akt Inhibitor ISC-4 Synergizes with Cetuximab in 5-FU-Resistant Colon Cancer Plos One. 8. DOI: 10.1371/Annotation/Aaa12360-0C90-42C3-Bc43-D00022B68B81 |
0.499 |
|
| 2013 |
Ishizawa J, Kojima K, Dilip A, Ruvolo VR, Carter BZ, Allen JE, Neelapu SS, McDonnell TJ, Talekar MK, El-Deiry WS, Kwak LW, Andreeff M. ONC201 Exerts p53-Independent Cytotoxicity Through TRAIL and DR5 Induction In Mantle Cell Lymphomas Blood. 122: 3822-3822. DOI: 10.1182/Blood.V122.21.3822.3822 |
0.642 |
|
| 2013 |
Talekar MK, Allen JE, El-Deiry WS. ONC201(TIC10) Induces TRAIL and Cell Death In Preclinical Models Of Pediatric Lymphoma Blood. 122: 1671-1671. DOI: 10.1182/Blood.V122.21.1671.1671 |
0.637 |
|
| 2013 |
Hong B, Heuvel AVD, Kopelovich L, El-Deiry WS. Abstract LB-53: Prodigiosin rescues mutant p53 signaling and antitumor effects via p73 upregulation and disruption of mutant p53:p73 interaction. Cancer Research. 73. DOI: 10.1158/1538-7445.Am2013-Lb-53 |
0.429 |
|
| 2013 |
Talekar MK, Allen JE, El-Deiry WS. Abstract LB-307: TRAIL-inducing agent -TIC10 and combinatorial therapeutics in pediatric lymphoma: a targeted approach. Cancer Research. 73. DOI: 10.1158/1538-7445.Am2013-Lb-307 |
0.625 |
|
| 2013 |
Zhou L, Zhang S, Dicker DT, Rehemtulla A, El-Deiry WS. Abstract 723: Anticancer ERK kinase inhibitor screening with molecular imaging. Cancer Research. 73: 723-723. DOI: 10.1158/1538-7445.Am2013-723 |
0.404 |
|
| 2013 |
Abdulghani J, Gallant J, Whitcomb T, Dicker D, Goldenberg D, Smith CD, Finnberg N, El-Deiry WS. Abstract 608: Quinacrine and sorafenib as potential combination for anaplastic thyroid carcinoma. Cancer Research. 73: 608-608. DOI: 10.1158/1538-7445.Am2013-608 |
0.468 |
|
| 2013 |
Matthew EM, Gallant J, Zhou L, Yang Z, Drabick JJ, Truica CI, Lamparella NE, Dicker DT, El-Deiry WS. Abstract 5104: Isolation, culture and immunophenotyping of live patient-derived circulating tumor cells. Cancer Research. 73: 5104-5104. DOI: 10.1158/1538-7445.Am2013-5104 |
0.424 |
|
| 2013 |
Harouaka R, Zhou M, Yeh Y, Truica C, Das A, Kaifi J, El-Deiry W, Liu X, Belani C, Baney T, Allerton J, Zheng S. Abstract 5102: Analysis of CTCs enriched from whole blood samples of Breast, Lung and Colorectal cancer patients with a flexible microspring array device. Cancer Research. 73: 5102-5102. DOI: 10.1158/1538-7445.Am2013-5102 |
0.406 |
|
| 2013 |
Peters KL, Dicker DT, Woolfson A, El-Deiry WS. Abstract 3998: The IGF1 receptor/insulin receptor dual kinase inhibitor BMS-754807 targets the cancer stem cell population in addition to its synergism with Lapatinib in colorectal cancer. Cancer Research. 73: 3998-3998. DOI: 10.1158/1538-7445.Am2013-3998 |
0.454 |
|
| 2013 |
Prabhu VV, Allen JE, Dicker DT, Ding Y, El-Deiry WS. Abstract 3732: Therapeutic targeting of colorectal cancer stem cells by TRAIL-inducing small molecule TIC10. Cancer Research. 73: 3732-3732. DOI: 10.1158/1538-7445.Am2013-3732 |
0.649 |
|
| 2013 |
Allen JE, Patel AS, Dicker DT, Sheehan JM, Glantz M, El-Deiry WS. Abstract 3483: Modeling circulating tumor cells in the peripheral blood and CSF of breast cancer patients. Cancer Research. 73: 3483-3483. DOI: 10.1158/1538-7445.Am2013-3483 |
0.56 |
|
| 2013 |
Imperato GH, Allen JE, El-Deiry WS. Abstract 2949: Characterization of TIC10, a novel small molecule inducer of TRAIL, in combination with chemotherapy for lymphomain vitro. Cancer Research. 73: 2949-2949. DOI: 10.1158/1538-7445.Am2013-2949 |
0.645 |
|
| 2013 |
Lim B, Dolloff NG, Allen JE, Dicker DT, El-Deiry WS. Abstract 2943: Lapatinib restores TRAIL-mediated apoptosis in TRAIL-resistant Triple Negative Breast Cancer (TNBC) through an off-target strategy that appears to be independent of increased death receptor expression. Cancer Research. 73: 2943-2943. DOI: 10.1158/1538-7445.Am2013-2943 |
0.628 |
|
| 2013 |
Crowder RN, Dicker DT, El-Deiry WS. Abstract 2938: Altered caspase-8 protein expression and activity in TRAIL-resistant normal human fibroblasts. Cancer Research. 73: 2938-2938. DOI: 10.1158/1538-7445.Am2013-2938 |
0.472 |
|
| 2013 |
Warfel NA, Dolloff NG, El-Deiry WS. Abstract 2935: Cyclin-dependent kinase 1 regualtes HIF-1α expression to promote tumorigenesis. Cancer Research. 73: 2935-2935. DOI: 10.1158/1538-7445.Am2013-2935 |
0.396 |
|
| 2013 |
Gokare PR, Finnberg N, Allen J, Dai J, El-Deiry W. Abstract 2197: p53-dependent expression of the fluorouracil (5-FU) catabolic enzyme dihydropyrimidine dehydrogenase (DPD) in mouse liver. Cancer Research. 73: 2197-2197. DOI: 10.1158/1538-7445.Am2013-2197 |
0.549 |
|
| 2013 |
Heuvel APvd, Wang W, Kopelovich L, El-Deiry WS. Abstract 2188: A screen to identify novel p53 family member activity-restoring compounds with a focus on p73. Cancer Research. 73: 2188-2188. DOI: 10.1158/1538-7445.Am2013-2188 |
0.459 |
|
| 2013 |
Zhang S, Zhou L, Hong B, Warfel N, heuvel AVd, Dicker D, Kopelovich L, El-Deiry W. Abstract 2171: A new small molecule compound restoring p53 pathway induces cell death via active p73 and degradation of mutant p53 in colorectal cancer cells. Cancer Research. 73: 2171-2171. DOI: 10.1158/1538-7445.Am2013-2171 |
0.491 |
|
| 2013 |
Allen JE, El-Deiry WS. Abstract 2059: Kinase library siRNA screen identifies KSR1 as a synergistic therapeutic target in combination with TIC10. Cancer Research. 73: 2059-2059. DOI: 10.1158/1538-7445.Am2013-2059 |
0.578 |
|
| 2013 |
Das A, Dicker DT, Harouaka R, Zheng S, Warfel N, Staveley-O'Carroll KF, El-Deiry WS, Kaifi JT. Abstract 1452: Perioperative detection of circulating tumor cells in patients undergoing colorectal cancer liver and lung metastasectomy : Comparing CellSearch and FMSA technologies and investigating the role of EMT . Cancer Research. 73: 1452-1452. DOI: 10.1158/1538-7445.Am2013-1452 |
0.374 |
|
| 2013 |
Lulla A, Stessman H, Dicker D, Ness BV, El-Deiry W, Dolloff NG. Abstract 1020: VRC2, a novel bortezomib re-sensitizing compound for the treatment of multiple myeloma. Cancer Research. 73: 1020-1020. DOI: 10.1158/1538-7445.Am2013-1020 |
0.372 |
|
| 2013 |
Lim B, Dolloff N, Allen J, Dicker D, El-Deiry W. Abstract P6-02-01: Elucidating the change of TRAIL sensitivity in basal like TNBC cell lines by lapatinib, and further therapeutic implication Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-P6-02-01 |
0.635 |
|
| 2013 |
Ambady P, Holdhoff M, Ferrigno C, Grossman S, Anderson MD, Liu D, Conrad C, Penas-Prado M, Gilbert MR, Yung AWK, Groot Jd, Aoki T, Nishikawa R, Sugiyama K, Nonoguchi N, ... ... El-Deiry W, et al. Neuro/Medical Oncology Neuro-Oncology. 15: 120-120. DOI: 10.1093/Neuonc/Not182 |
0.394 |
|
| 2013 |
Kaifi J, Kunkel M, Allen J, Dicker D, Das A, Gusani N, Reed M, Kimchi E, Staveley-O'Carroll K, El-Deiry W. Presence of Circulating Tumor Cells in Patients With Resectable Colorectal Cancer Lung Metastases is A Potential Indicator for Extrathoracic Disease Journal of Surgical Research. 179: 285. DOI: 10.1016/J.Jss.2012.10.558 |
0.543 |
|
| 2012 |
Crowder RN, El-Deiry WS. Caspase-8 regulation of trail-mediated cell death Experimental Oncology. 34: 160-164. PMID 23070000 |
0.389 |
|
| 2012 |
Prabhu VV, Allen JE, Hong B, Zhang S, Cheng H, El-Deiry WS. Therapeutic targeting of the p53 pathway in cancer stem cells. Expert Opinion On Therapeutic Targets. 16: 1161-74. PMID 22998602 DOI: 10.1517/14728222.2012.726985 |
0.593 |
|
| 2012 |
Dolloff NG, Allen JE, Dicker DT, Aqui N, Vogl D, Malysz J, Talamo G, El-Deiry WS. Sangivamycin-like molecule 6 exhibits potent anti-multiple myeloma activity through inhibition of cyclin-dependent kinase-9. Molecular Cancer Therapeutics. 11: 2321-30. PMID 22964485 DOI: 10.1158/1535-7163.Mct-12-0578 |
0.574 |
|
| 2012 |
Cheng H, Hong B, Zhou L, Allen JE, Tai G, Humphreys R, Dicker DT, Liu YY, El-Deiry WS. Mitomycin C potentiates TRAIL-induced apoptosis through p53-independent upregulation of death receptors: evidence for the role of c-Jun N-terminal kinase activation. Cell Cycle (Georgetown, Tex.). 11: 3312-23. PMID 22895172 DOI: 10.4161/Cc.21670 |
0.641 |
|
| 2012 |
Allen JE, El-Deiry WS. Regulation of the human TRAIL gene. Cancer Biology & Therapy. 13: 1143-51. PMID 22892844 DOI: 10.4161/Cbt.21354 |
0.592 |
|
| 2012 |
Allen JE, Ferrini R, Dicker DT, Batzer G, Chen E, Oltean DI, Lin B, Renshaw MW, Kretz-Rommel A, El-Deiry WS. Targeting TRAIL death receptor 4 with trivalent DR4 Atrimer complexes. Molecular Cancer Therapeutics. 11: 2087-95. PMID 22802267 DOI: 10.1158/1535-7163.Mct-12-0366 |
0.564 |
|
| 2012 |
Zhou L, El-Deiry W, Wang W, Ingram ME, Katz SI. Extracellular protease imaging for cell mass tracking of xenografted human malignant pleural mesothelioma. Oncology Reports. 28: 883-8. PMID 22751990 DOI: 10.3892/Or.2012.1888 |
0.392 |
|
| 2012 |
Prabhu VV, Warfel NA, El-Deiry WS. CTGF-mediated autophagy-senescence transition in tumor stroma promotes anabolic tumor growth and metastasis. Cell Cycle (Georgetown, Tex.). 11: 2592-3. PMID 22751431 DOI: 10.4161/Cc.21240 |
0.338 |
|
| 2012 |
Allen J, Patel A, Dicker D, Sheehan J, Glantz MJ, El-Deiry W. Compartmentalization of tumor cells to the CSF or peripheral blood of a breast cancer patient with CNS metastasis. Journal of Clinical Oncology. 30: e11544-e11544. DOI: 10.1200/Jco.2012.30.15_Suppl.E11544 |
0.537 |
|
| 2012 |
Matthew EM, Zhou L, Vijayvergia N, Dicker DT, Gustafson KS, Cooper HS, Ross EA, Lim B, Harouaka R, Zheng S, Lamparella NE, Drabick JJ, Truica CI, Yang Z, El-Deiry WS. Abstract 1600: A multiplexed marker-based algorithm for diagnosis of carcinoma of unknown primary using circulating tumor cells Cancer Research. 75: 1600-1600. DOI: 10.1158/1538-7445.Am2015-1600 |
0.373 |
|
| 2012 |
Warfel NA, El-Deiry WS. Abstract LB-484: Molecular regulation of HIF-1α by CDK1 and the cell cycle Cancer Research. 72. DOI: 10.1158/1538-7445.Am2012-Lb-484 |
0.369 |
|
| 2012 |
Sheikh HS, Matthew E, El-Deiry WS. Abstract 745: Development of gamma-H2AX assay to assess toxicity and efficacy from chemotherapy in circulating tumor cells (CTCs) and peripheral blood lymphocytes Cancer Research. 72: 745-745. DOI: 10.1158/1538-7445.Am2012-745 |
0.394 |
|
| 2012 |
Dolloff NG, Zhou L, Peters K, Navaraj A, Allen J, Das A, Dicker D, El-Deiry W. Abstract 5665: Multiplexing markers of response to sorafenib/mapatumumab combination therapy in hepatocellular carcinoma circulating tumor cells Cancer Research. 72: 5665-5665. DOI: 10.1158/1538-7445.Am2012-5665 |
0.505 |
|
| 2012 |
Allen JE, Patel AS, Dicker DT, Sheehan JM, Glantz MJ, El-Deiry WS. Abstract 5565: Circulating tumor cells in the peripheral blood and cerebrospinal fluid of patients with central nervous system metastases Cancer Research. 72: 5565-5565. DOI: 10.1158/1538-7445.Am2012-5565 |
0.567 |
|
| 2012 |
Zhang S, Hong B, Kopelovich L, El-Deiry WS. Abstract 4828: A novel small molecule p53-pathway restoring compound suppresses colorectal cancer cells via p73 Cancer Research. 72: 4828-4828. DOI: 10.1158/1538-7445.Am2012-4828 |
0.542 |
|
| 2012 |
Zhou L, Yang Z, Baker M, Dicker DT, El-Deiry WS. Abstract 4058: Multispectral imaging of mismatch repair proteins in colorectal cancers and tumor cells isolated from blood Cancer Research. 72: 4058-4058. DOI: 10.1158/1538-7445.Am2012-4058 |
0.415 |
|
| 2012 |
Abdulghani J, Gallant J, Whitcomb T, Dicker D, Smith CD, Goldenberg D, El-Deiry WS. Abstract 3722: Quinacrine and sorafenib combination as potential therapy for anaplastic thyroid cancer Cancer Research. 72: 3722-3722. DOI: 10.1158/1538-7445.Am2012-3722 |
0.428 |
|
| 2012 |
Das A, Joudeh J, Peters KL, Allen JE, Zheng S, Dicker DT, Yang Z, El-Deiry WS. Abstract 3413: A population of metastatic colorectal cancer (mCRC) patients with radiologically proven liver metastasis and EpCAM expressing primary tumors show low circulating tumor cell counts by Veridex Cellsearch Cancer Research. 72: 3413-3413. DOI: 10.1158/1538-7445.Am2012-3413 |
0.558 |
|
| 2012 |
Peters KL, Dicker DT, Abdallah K, Dhar A, Woolfson A, El-Deiry WS. Abstract 3235: The IGF1 inhibitor BMS-754807 synergizes with Lapatinib in colorectal cancer cell lines Cancer Research. 72: 3235-3235. DOI: 10.1158/1538-7445.Am2012-3235 |
0.483 |
|
| 2012 |
Gallant J, Cheng H, Harouaka R, Zheng S, El-Deiry WS. Abstract 3196: In vivo drug sensitivity testing of CTCs isolated using the FMSA device Cancer Research. 72: 3196-3196. DOI: 10.1158/1538-7445.Am2012-3196 |
0.41 |
|
| 2012 |
Cheng H, Gallant J, Harouaka R, Zheng S, El-Deiry W. Abstract 3187:Ex vivocharacterization of CTCs isolated using the FMSA device Cancer Research. 72: 3187-3187. DOI: 10.1158/1538-7445.Am2012-3187 |
0.379 |
|
| 2012 |
Cheng H, Hong B, Zhou L, Allen J, Dicker D, El-Deiry W. Abstract 2758: Mitomycin C potentiates TRAIL-induced apoptosis through p53-independent upregulation of death receptors: Evidence for the role of C-Jun N-terminal kinase activation Cancer Research. 72: 2758-2758. DOI: 10.1158/1538-7445.Am2012-2758 |
0.653 |
|
| 2012 |
Crowder RN, Dicker DT, El-Deiry WS. Abstract 252: Altered caspase-8 localization and decreased caspase-8 sumoylation in TRAIL-resistant normal human fibroblasts Cancer Research. 72: 252-252. DOI: 10.1158/1538-7445.Am2012-252 |
0.464 |
|
| 2012 |
Das A, Whitcomb TL, Allen JE, Dicker DT, Peters KL, El-Deiry WS. Abstract 2393: Isolation and characterization of circulating tumor cells in a mouse model of colorectal cancer Cancer Research. 72: 2393-2393. DOI: 10.1158/1538-7445.Am2012-2393 |
0.564 |
|
| 2012 |
Matthew EM, Yang Z, El-Deiry WS. Abstract 2187: Plk2 loss and mTOR signaling in advanced colorectal cancer Cancer Research. 72: 2187-2187. DOI: 10.1158/1538-7445.Am2012-2187 |
0.445 |
|
| 2012 |
Allen JE, Krigsfeld G, Patel AS, Wu GS, Dicker DT, El-Deiry WS. Abstract 1935: Potent anti-tumor effects of TIC10 require Foxo3a and TRAIL gene upregulation Cancer Research. 72: 1935-1935. DOI: 10.1158/1538-7445.Am2012-1935 |
0.64 |
|
| 2012 |
Navaraj A, Dicker DT, El-Deiry WS. Abstract 1400: Mouse models for detection of circulating tumor cells from breast cancer Cancer Research. 72: 1400-1400. DOI: 10.1158/1538-7445.Am2012-1400 |
0.393 |
|
| 2012 |
Scata KA, El-Deiry WS. Abstract 1191: Managing the cross talk: BRCA1 and its regulation of the p53 family, E2f1/Rb and apoptosis Cancer Research. 72: 1191-1191. DOI: 10.1158/1538-7445.Am2012-1191 |
0.511 |
|
| 2012 |
Hong B, Dicker DT, Kopelovich L, El-Deiry WS. Abstract 1172: Prodigiosin and its structural analogue rescue deficient p53 pathway signaling and anti-tumor effects via p73 upregulation in p53 mutant and null colorectal cancer cells Cancer Research. 72: 1172-1172. DOI: 10.1158/1538-7445.Am2012-1172 |
0.506 |
|
| 2012 |
Prabhu VV, Hong B, Allen JE, Dicker DT, Navaraj A, Kopelovich L, El-Deiry WS. Abstract 1170: Anti-tumor effects of p53-pathway restoring compound Prodigiosin in colorectal cancer involve effects on apoptotic signaling, angiogenesis and cancer stem cells Cancer Research. 72: 1170-1170. DOI: 10.1158/1538-7445.Am2012-1170 |
0.664 |
|
| 2011 |
Patel AS, Allen JE, Dicker DT, Peters KL, Sheehan JM, Glantz MJ, El-Deiry WS. Identification and enumeration of circulating tumor cells in the cerebrospinal fluid of breast cancer patients with central nervous system metastases. Oncotarget. 2: 752-60. PMID 21987585 DOI: 10.18632/Oncotarget.336 |
0.556 |
|
| 2011 |
Finnberg NK, Hart LS, Dolloff NG, Rodgers ZB, Dicker DT, El-Deiry WS. High-resolution imaging and antitumor effects of GFP(+) bone marrow-derived cells homing to syngeneic mouse colon tumors. The American Journal of Pathology. 179: 2169-76. PMID 21975022 DOI: 10.1016/J.Ajpath.2011.07.028 |
0.377 |
|
| 2011 |
Cazanave SC, Mott JL, Bronk SF, Werneburg NW, Fingas CD, Meng XW, Finnberg N, El-Deiry WS, Kaufmann SH, Gores GJ. Death receptor 5 signaling promotes hepatocyte lipoapoptosis. The Journal of Biological Chemistry. 286: 39336-48. PMID 21941003 DOI: 10.1074/Jbc.M111.280420 |
0.424 |
|
| 2011 |
Kline CL, Sheikh HS, Scicchitano A, Gingrich R, Beachler C, Finnberg NK, Liao J, Sivik J, El-Deiry WS. Preliminary observations indicate variable patterns of plasma 5-fluorouracil (5-FU) levels during dose optimization of infusional 5-FU in colorectal cancer patients. Cancer Biology & Therapy. 12: 557-68. PMID 21931273 DOI: 10.4161/Cbt.12.7.18059 |
0.305 |
|
| 2011 |
Zhou L, Wang W, Dicker DT, Humphreys RC, El-Deiry WS. Prediction of proapoptotic anticancer therapeutic response in vivo based on cell death visualization and TRAIL death ligand-receptor interaction. Cancer Biology & Therapy. 12: 335-48. PMID 21785270 DOI: 10.4161/Cbt.12.4.17174 |
0.48 |
|
| 2011 |
Dolloff NG, Ma X, Dicker DT, Humphreys RC, Li LZ, El-Deiry WS. Spectral imaging-based methods for quantifying autophagy and apoptosis Cancer Biology and Therapy. 12: 349-356. PMID 21757995 DOI: 10.4161/Cbt.12.4.17175 |
0.363 |
|
| 2011 |
Gallant JN, Allen JE, Smith CD, Dicker DT, Wang W, Dolloff NG, Navaraj A, El-Deiry WS. Quinacrine synergizes with 5-fluorouracil and other therapies in colorectal cancer. Cancer Biology & Therapy. 12: 239-51. PMID 21725213 DOI: 10.4161/Cbt.12.3.17034 |
0.583 |
|
| 2011 |
Wang W, Gallant JN, Katz SI, Dolloff NG, Smith CD, Abdulghani J, Allen JE, Dicker DT, Hong B, Navaraj A, El-Deiry WS. Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL and chemotherapeutic agents. Cancer Biology & Therapy. 12: 229-38. PMID 21725212 DOI: 10.4161/Cbt.12.3.17033 |
0.603 |
|
| 2011 |
Hart LS, Dolloff NG, Dicker DT, Koumenis C, Christensen JG, Grimberg A, El-Deiry WS. Human colon cancer stem cells are enriched by insulin-like growth factor-1 and are sensitive to figitumumab. Cell Cycle (Georgetown, Tex.). 10: 2331-8. PMID 21720213 DOI: 10.4161/Cc.10.14.16418 |
0.428 |
|
| 2011 |
Kuribayashi K, Finnberg N, Jeffers JR, Zambetti GP, El-Deiry WS. The relative contribution of pro-apoptotic p53-target genes in the triggering of apoptosis following DNA damage in vitro and in vivo. Cell Cycle (Georgetown, Tex.). 10: 2380-9. PMID 21709442 DOI: 10.4161/Cc.10.14.16588 |
0.495 |
|
| 2011 |
Allen JE, El-Deiry WS. Oxaliplatin uses JNK to restore TRAIL sensitivity in cancer cells through Bcl-xL inactivation. Gastroenterology. 141: 430-4. PMID 21699898 DOI: 10.1053/J.Gastro.2011.06.026 |
0.601 |
|
| 2011 |
Dolloff NG, Mayes PA, Hart LS, Dicker DT, Humphreys R, El-Deiry WS. Off-target lapatinib activity sensitizes colon cancer cells through TRAIL death receptor up-regulation. Science Translational Medicine. 3: 86ra50. PMID 21653830 DOI: 10.1126/Scitranslmed.3001384 |
0.687 |
|
| 2011 |
Mayes PA, Dolloff NG, Daniel CJ, Liu JJ, Hart LS, Kuribayashi K, Allen JE, Jee DI, Dorsey JF, Liu YY, Dicker DT, Brown JM, Furth EE, Klein PS, Sears RC, ... El-Deiry WS, et al. Overcoming hypoxia-induced apoptotic resistance through combinatorial inhibition of GSK-3β and CDK1. Cancer Research. 71: 5265-75. PMID 21646472 DOI: 10.1158/0008-5472.Can-11-1383 |
0.759 |
|
| 2011 |
Katz SI, Zhou L, Ferrara TA, Wang W, Mayes PA, Smith CD, El-Deiry WS. FLT-PET may not be a reliable indicator of therapeutic response in p53-null malignancy. International Journal of Oncology. 39: 91-100. PMID 21537838 DOI: 10.3892/Ijo.2011.1019 |
0.656 |
|
| 2011 |
Navaraj A, Dicker DT, Dolloff N, El-Deiry WS. Abstract LB-57: Multiplexed detection of phospho-ERK as a marker of H-Ras signaling, EGFR and cancer stem cell marker expression in breast cancer cells recovered from human blood Cancer Research. 71. DOI: 10.1158/1538-7445.Am2011-Lb-57 |
0.406 |
|
| 2011 |
Gallant J, Wang W, Dolloff NG, Allen JE, El-Deiry WS. Abstract 674: Novel combinatorial quinacrine cancer therapies for advanced colon cancer Cancer Research. 71: 674-674. DOI: 10.1158/1538-7445.Am2011-674 |
0.523 |
|
| 2011 |
Hong B, Chen F, Dicker DT, El-Deiry WS. Abstract 607: Restoration of p53 pathway signaling and apoptotic induction by prodigiosin and its structurally-related compound (NSC247562) in p53-deficient human colon carcinoma cells Cancer Research. 71: 607-607. DOI: 10.1158/1538-7445.Am2011-607 |
0.48 |
|
| 2011 |
Das A, Allen JE, Dicker DT, Peters KL, Joudeh J, El-Deiry WS. Abstract 5248: Quantum dot multiplexing of prognostic marker and stem cell marker expression in colorectal cancer circulating tumor cells Cancer Research. 71: 5248-5248. DOI: 10.1158/1538-7445.Am2011-5248 |
0.542 |
|
| 2011 |
Allen JE, Krigsfeld G, Mayes PA, Patel L, Dicker DT, Wu GS, El-Deiry WS. Abstract 4502: The small molecule TIC10 has potent anticancer efficacy mediated by induction of TRAIL production in normal and tumor cells Cancer Research. 71: 4502-4502. DOI: 10.1158/1538-7445.Am2011-4502 |
0.775 |
|
| 2011 |
Dolloff NG, Mayes P, Hart L, Dicker D, Humphreys R, El-Deiry W. Abstract 4101: Off-target lapatinib activity up-regulates TRAIL death receptors in colon cancer cells Cellular and Molecular Biology. 71: 4101-4101. DOI: 10.1158/1538-7445.Am2011-4101 |
0.671 |
|
| 2011 |
Abdulghani J, Allen JE, Dicker DT, Smith CD, Humphreys RC, El-Deiry WS. Abstract 4097: Sorafenib sensitizes solid tumors to TRAIL or TRAIL receptor agonist antibodies Cellular and Molecular Biology. 71: 4097-4097. DOI: 10.1158/1538-7445.Am2011-4097 |
0.505 |
|
| 2011 |
Crowder RN, Dicker DT, El-Deiry WS. Abstract 4095: Decreased caspase 8 protein expression and incomplete caspase 3 activation in TRAIL-resistant normal human fibroblasts and epithelial cells Cellular and Molecular Biology. 71: 4095-4095. DOI: 10.1158/1538-7445.Am2011-4095 |
0.395 |
|
| 2011 |
Peters KL, Allen JE, Dicker DT, Das A, Joudeh J, El-Deiry WS. Abstract 3818: CTC profiling: Integration of biomarker analysis with current Veridex CellSearch technology Cancer Research. 71: 3818-3818. DOI: 10.1158/1538-7445.Am2011-3818 |
0.578 |
|
| 2011 |
Finnberg NK, Arunasalam N, Lang K, Cerniglia G, Motoyama N, Zhou B, El-Deiry WS. Abstract 2963: Pharmacologic Chk2-inhibition promotes increased killing of human colorectal cancer cells and protects from gastrointestinal toxicity following Irinotecan/trail death-receptor agonists (TDRA) Cancer Research. 71: 2963-2963. DOI: 10.1158/1538-7445.Am2011-2963 |
0.483 |
|
| 2011 |
Scata KA, El-Deiry WS. Abstract 220: BRCA1 regulates p53 target expression via DNp73 Cancer Research. 71: 220-220. DOI: 10.1158/1538-7445.Am2011-220 |
0.469 |
|
| 2011 |
Dolloff NG, Talamo G, Dicker DT, El-Deiry WS. Abstract C77: Sangivamycin-like molecule 6 (SLM6) exhibits potent and selective anti-multiple myeloma activity through inhibition of P-TEFb. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-C77 |
0.48 |
|
| 2010 |
Dews M, Fox JL, Hultine S, Sundaram P, Wang W, Liu YY, Furth E, Enders GH, El-Deiry W, Schelter JM, Cleary MA, Thomas-Tikhonenko A. The myc-miR-17~92 axis blunts TGF{beta} signaling and production of multiple TGF{beta}-dependent antiangiogenic factors. Cancer Research. 70: 8233-46. PMID 20940405 DOI: 10.1158/0008-5472.Can-10-2412 |
0.603 |
|
| 2010 |
Allen JE, El-Deiry WS. Circulating Tumor Cells and Colorectal Cancer. Current Colorectal Cancer Reports. 6: 212-220. PMID 20890370 DOI: 10.1007/S11888-010-0069-7 |
0.561 |
|
| 2010 |
Abdulghani J, El-Deiry WS. TRAIL receptor signaling and therapeutics. Expert Opinion On Therapeutic Targets. 14: 1091-108. PMID 20819019 DOI: 10.1517/14728222.2010.519701 |
0.438 |
|
| 2010 |
McGovern PE, Christofidou-Solomidou M, Wang W, Dukes F, Davidson T, El-Deiry WS. Anticancer activity of botanical compounds in ancient fermented beverages (review) International Journal of Oncology. 37: 5-14. PMID 20514391 DOI: 10.3892/Ijo_00000647 |
0.305 |
|
| 2010 |
Chen F, Wang W, El-Deiry WS. Current strategies to target p53 in cancer. Biochemical Pharmacology. 80: 724-30. PMID 20450892 DOI: 10.1016/J.Bcp.2010.04.031 |
0.469 |
|
| 2010 |
Hart LS, Dicker DT, Grimberg A, Christensen J, El-Deiry WS. Abstract 709: The fully human IGF-1 receptor antibody, CP-751,871, targets putative colon cancer stem cell populations Cancer Research. 70: 709-709. DOI: 10.1158/1538-7445.Am10-709 |
0.438 |
|
| 2010 |
Wang W, Katz SI, Abdulghani J, Dicker D, El-Deiry WS. Abstract 680: Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL via up-regulating DR5 and eradicating MCL-1 Cancer Research. 70: 680-680. DOI: 10.1158/1538-7445.Am10-680 |
0.487 |
|
| 2010 |
Dolloff NG, Hart LS, Mayes PA, Dicker DT, Humphreys RC, Gilmer TM, El-Deiry WS. Abstract 673: Novel anti-tumor activity of lapatinib derives from off-target up-regulation of TRAIL death receptors Cancer Research. 70: 673-673. DOI: 10.1158/1538-7445.Am10-673 |
0.706 |
|
| 2010 |
Allen JE, Patel L, Krigsfeld G, Mayes PA, Wu GS, El-Deiry WS. Abstract 5467: Breflate upregulates TRAIL gene transcription in Bax-null cells and induces TRAIL-mediated apoptosis independently of p53 in TRAIL-sensitive tumor lines Cancer Research. 70: 5467-5467. DOI: 10.1158/1538-7445.Am10-5467 |
0.774 |
|
| 2010 |
Dolloff NG, Hart LS, Mayes PA, El-Deiry WS. Abstract 5044: Dual GSK-3β/CDK inhibitors induce multiple myeloma cell death and eliminate putative cancer stem cell populations Cancer Research. 70: 5044-5044. DOI: 10.1158/1538-7445.Am10-5044 |
0.668 |
|
| 2010 |
Hart LS, Finnberg N, Dolloff NG, Rodgers ZB, Dicker DT, Thomas-Tikhonenko A, El-Deiry WS. Abstract 4326: High-resolution imaging and antitumor effects of GFP(+) bone marrow-derived cells homing to syngeneic mouse colon tumors Cancer Research. 70: 4326-4326. DOI: 10.1158/1538-7445.Am10-4326 |
0.663 |
|
| 2010 |
Natsuizaka M, Kalman RA, Ohashi S, Takaoka M, Gimotty P, El-Deiry WS, Klein-Szanto A, Diehl JA, Herlyn M, Nakagawa H. Abstract 2294: IGF-independent regulation of EMT by insulin-like growth factor binding protein-3 in transformed human esophageal cells Cancer Research. 70: 2294-2294. DOI: 10.1158/1538-7445.Am10-2294 |
0.447 |
|
| 2010 |
Finnberg NK, Arunasalam N, Lang K, Cerniglia G, Motoyama N, Zhou B, El-Deiry W. Abstract 127: Targeting of dr5/trail-r2 in combination with irinotecan triggersp53- andchk2-dependent gastrointestinal toxicity in mice in vivo and synergistic cell death in human gastrointestinal epithelial cells in vitro Cancer Research. 70: 127-127. DOI: 10.1158/1538-7445.Am10-127 |
0.404 |
|
| 2010 |
Scata KA, El-Deiry WS. Abstract 125: The DNp73 isoform provides novel insights into the regulation of p53 by BRCA1 to favor cell survival over cell death Cellular and Molecular Biology. 70: 125-125. DOI: 10.1158/1538-7445.Am10-125 |
0.439 |
|
| 2010 |
Crowder RN, Dicker DT, El-Deiry WS. Abstract 1042: Diminished caspase 8 and c-Myc protein expression in human fibroblasts provides insight into normal cell resistance to TRAIL-mediated apoptosis Cancer Research. 70: 1042-1042. DOI: 10.1158/1538-7445.Am10-1042 |
0.515 |
|
| 2010 |
Allen JE, El-Deiry WS. Circulating tumor cells and colorectal cancer Current Colorectal Cancer Reports. 6: 212-220. DOI: 10.1007/s11888-010-0069-7 |
0.53 |
|
| 2009 |
Matthew EM, Hart LS, Astrinidis A, Navaraj A, Dolloff NG, Dicker DT, Henske EP, El-Deiry WS. The p53 target Plk2 interacts with TSC proteins impacting mTOR signaling, tumor growth and chemosensitivity under hypoxic conditions. Cell Cycle (Georgetown, Tex.). 8: 4168-75. PMID 20054236 DOI: 10.4161/Cc.8.24.10800 |
0.465 |
|
| 2009 |
Navaraj A, Finnberg N, Dicker DT, Yang W, Matthew EM, El-Deiry WS. Reduced cell death, invasive and angiogenic features conferred by BRCA1-deficiency in mammary epithelial cells transformed with H-Ras. Cancer Biology & Therapy. 8: 2417-44. PMID 20038817 DOI: 10.4161/Cbt.8.24.10850 |
0.417 |
|
| 2009 |
Katz SI, Zhou L, Chao G, Smith CD, Ferrara T, Wang W, Dicker DT, El-Deiry WS. Sorafenib inhibits ERK1/2 and MCL-1(L) phosphorylation levels resulting in caspase-independent cell death in malignant pleural mesothelioma. Cancer Biology & Therapy. 8: 2406-16. PMID 20038816 DOI: 10.4161/Cbt.8.24.10824 |
0.436 |
|
| 2009 |
Dorsey JF, Mintz A, Tian X, Dowling ML, Plastaras JP, Dicker DT, Kao GD, El-Deiry WS. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and paclitaxel have cooperative in vivo effects against glioblastoma multiforme cells. Molecular Cancer Therapeutics. 8: 3285-95. PMID 19996278 DOI: 10.1158/1535-7163.Mct-09-0415 |
0.499 |
|
| 2009 |
Huang C, Zhang XM, Tavaluc RT, Hart LS, Dicker DT, Wang W, El-Deiry WS. The combination of 5-fluorouracil plus p53 pathway restoration is associated with depletion of p53-deficient or mutant p53-expressing putative colon cancer stem cells. Cancer Biology & Therapy. 8: 2186-93. PMID 19923910 DOI: 10.4161/Cbt.8.22.10446 |
0.503 |
|
| 2009 |
Allen JE, Hart LS, Dicker DT, Wang W, El-Deiry WS. Visualization and enrichment of live putative cancer stem cell populations following p53 inactivation or Bax deletion using non-toxic fluorescent dyes. Cancer Biology & Therapy. 8: 2194-205. PMID 19923899 DOI: 10.4161/Cbt.8.22.10450 |
0.586 |
|
| 2009 |
Ide T, Brown-Endres L, Chu K, Ongusaha PP, Ohtsuka T, El-Deiry WS, Aaronson SA, Lee SW. GAMT, a p53-inducible modulator of apoptosis, is critical for the adaptive response to nutrient stress. Molecular Cell. 36: 379-92. PMID 19917247 DOI: 10.1016/J.Molcel.2009.09.031 |
0.419 |
|
| 2009 |
Hart LS, El-Deiry WS. Cell death: a new Par-4 the TRAIL. Cell. 138: 220-2. PMID 19632170 DOI: 10.1016/J.Cell.2009.07.007 |
0.39 |
|
| 2009 |
Galluzzi L, Aaronson SA, Abrams J, Alnemri ES, Andrews DW, Baehrecke EH, Bazan NG, Blagosklonny MV, Blomgren K, Borner C, Bredesen DE, Brenner C, Castedo M, Cidlowski JA, Ciechanover A, ... ... El-Deiry WS, et al. Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes. Cell Death and Differentiation. 16: 1093-107. PMID 19373242 DOI: 10.1038/Cdd.2009.44 |
0.403 |
|
| 2009 |
Lu C, El-Deiry WS. Targeting p53 for enhanced radio- and chemo-sensitivity. Apoptosis : An International Journal On Programmed Cell Death. 14: 597-606. PMID 19259822 DOI: 10.1007/S10495-009-0330-1 |
0.437 |
|
| 2009 |
Kroemer G, Galluzzi L, Vandenabeele P, Abrams J, Alnemri ES, Baehrecke EH, Blagosklonny MV, El-Deiry WS, Golstein P, Green DR, Hengartner M, Knight RA, Kumar S, Lipton SA, Malorni W, et al. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death and Differentiation. 16: 3-11. PMID 18846107 DOI: 10.1038/Cdd.2008.150 |
0.408 |
|
| 2009 |
Allen JE, Hart LS, Dicker DT, Wang W, El-Deiry WS. Visualization and enrichment of live putative cancer stem cell populations following p53 inactivation or Bax deletion using non-toxic fluorescent dyes Cancer Biology and Therapy. 8: 2193-2204. DOI: 10.4161/cbt.8.22.10450 |
0.464 |
|
| 2009 |
Liao W, Fujita Ki, Xiao Q, Tchikov V, Yang W, Gunsor M, Garfield S, Goldsmith P, El-Deiry WS, Schutze S, Srinivasula SM. Response: CARP1 regulates induction of NF-κB by TNFα Current Biology. 19: R17-R19. DOI: 10.1016/J.Cub.2008.11.041 |
0.37 |
|
| 2008 |
Lu C, Wang W, El-Deiry WS. Non-genotoxic anti-neoplastic effects of ellipticine derivative NSC176327 in p53-deficient human colon carcinoma cells involve stimulation of p73. Cancer Biology & Therapy. 7: 2039-46. PMID 19106635 DOI: 10.4161/Cbt.7.12.7461 |
0.494 |
|
| 2008 |
Plastaras JP, Dorsey JF, Carroll K, Kim SH, Birnbaum MJ, El-Deiry WS. Role of PI3K/Akt signaling in TRAIL- and radiation-induced gastrointestinal apoptosis. Cancer Biology & Therapy. 7: 2047-53. PMID 19106634 DOI: 10.4161/Cbt.7.12.7570 |
0.367 |
|
| 2008 |
Kuribayashi K, Krigsfeld G, Wang W, Xu J, Mayes PA, Dicker DT, Wu GS, El-Deiry WS. TNFSF10 (TRAIL), a p53 target gene that mediates p53-dependent cell death. Cancer Biology & Therapy. 7: 2034-8. PMID 19106633 DOI: 10.4161/Cbt.7.12.7460 |
0.727 |
|
| 2008 |
Finnberg N, Wambi C, Ware JH, Kennedy AR, El-Deiry WS. Gamma-radiation (GR) triggers a unique gene expression profile associated with cell death compared to proton radiation (PR) in mice in vivo. Cancer Biology & Therapy. 7: 2023-33. PMID 19106632 DOI: 10.4161/Cbt.7.12.7417 |
0.396 |
|
| 2008 |
Bassett EA, Wang W, Rastinejad F, El-Deiry WS. Structural and functional basis for therapeutic modulation of p53 signaling. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 6376-86. PMID 18927276 DOI: 10.1158/1078-0432.Ccr-08-1526 |
0.435 |
|
| 2008 |
Mayes PA, Dicker DT, Liu YY, El-Deiry WS. Noninvasive vascular imaging in fluorescent tumors using multispectral unmixing Biotechniques. 45: 459-464. PMID 18855773 DOI: 10.2144/000112946 |
0.579 |
|
| 2008 |
Kuribayashi K, Finnberg N, El-Deiry WS. Studying p53-dependent cell death in vitro and in vivo. Methods in Enzymology. 446: 159-73. PMID 18603121 DOI: 10.1016/S0076-6879(08)01609-1 |
0.339 |
|
| 2008 |
Hart LS, El-Deiry WS. Invincible, but not invisible: imaging approaches toward in vivo detection of cancer stem cells. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 2901-10. PMID 18539971 DOI: 10.1200/Jco.2008.16.9573 |
0.401 |
|
| 2008 |
Finnberg N, El-Deiry WS. TRAIL death receptors as tumor suppressors and drug targets. Cell Cycle (Georgetown, Tex.). 7: 1525-8. PMID 18469516 DOI: 10.4161/Cc.7.11.5975 |
0.413 |
|
| 2008 |
Kim M, Liao J, Dowling ML, Voong KR, Parker SE, Wang S, El-Deiry WS, Kao GD. TRAIL inactivates the mitotic checkpoint and potentiates death induced by microtubule-targeting agents in human cancer cells. Cancer Research. 68: 3440-9. PMID 18451172 DOI: 10.1158/0008-5472.Can-08-0014 |
0.473 |
|
| 2008 |
Liao W, Xiao Q, Tchikov V, Fujita K, Yang W, Wincovitch S, Garfield S, Conze D, El-Deiry WS, Schütze S, Srinivasula SM. CARP-2 is an endosome-associated ubiquitin ligase for RIP and regulates TNF-induced NF-kappaB activation. Current Biology : Cb. 18: 641-9. PMID 18450452 DOI: 10.1016/J.Cub.2008.04.017 |
0.306 |
|
| 2008 |
Kuribayashi K, El-Deiry WS. Regulation of programmed cell death by the p53 pathway. Advances in Experimental Medicine and Biology. 615: 201-21. PMID 18441595 DOI: 10.1007/978-1-4020-6554-5_10 |
0.499 |
|
| 2008 |
Noma K, Smalley KS, Lioni M, Naomoto Y, Tanaka N, El-Deiry W, King AJ, Nakagawa H, Herlyn M. The essential role of fibroblasts in esophageal squamous cell carcinoma-induced angiogenesis. Gastroenterology. 134: 1981-93. PMID 18439605 DOI: 10.1053/J.Gastro.2008.02.061 |
0.345 |
|
| 2008 |
Yang W, Dicker DT, Chen J, El-Deiry WS. CARPs enhance p53 turnover by degrading 14-3-3sigma and stabilizing MDM2. Cell Cycle (Georgetown, Tex.). 7: 670-82. PMID 18382127 DOI: 10.4161/Cc.7.5.5701 |
0.393 |
|
| 2008 |
Kim SH, Ricci MS, El-Deiry WS. Mcl-1: a gateway to TRAIL sensitization. Cancer Research. 68: 2062-4. PMID 18381408 DOI: 10.1158/0008-5472.Can-07-6278 |
0.476 |
|
| 2008 |
Yang W, Dolloff NG, El-Deiry WS. ERK and MDM2 prey on FOXO3a. Nature Cell Biology. 10: 125-6. PMID 18246039 DOI: 10.1038/Ncb0208-125 |
0.372 |
|
| 2008 |
Laguinge LM, Samara RN, Wang W, El-Deiry WS, Corner G, Augenlicht L, Mishra L, Jessup JM. DR5 receptor mediates anoikis in human colorectal carcinoma cell lines. Cancer Research. 68: 909-17. PMID 18245494 DOI: 10.1158/0008-5472.Can-06-1806 |
0.469 |
|
| 2008 |
Finnberg N, Klein-Szanto AJ, El-Deiry WS. TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis. The Journal of Clinical Investigation. 118: 111-23. PMID 18079962 DOI: 10.1172/Jci29900 |
0.378 |
|
| 2008 |
Wang W, El-Deiry WS. Restoration of p53 to limit tumor growth. Current Opinion in Oncology. 20: 90-6. PMID 18043262 DOI: 10.1097/Cco.0B013E3282F31D6F |
0.474 |
|
| 2008 |
McDonald EK, Dirisina R, Finnberg N, Barrett M, Goretsky T, Manjali J, Darweesh M, Brown J, El-Deiry WS, Barrett TA. M1684 The Roles of p53 and Death Receptor-5 in Augmenting Activated T-Cell Induced Apoptosis Gastroenterology. 134: A-397. DOI: 10.1016/S0016-5085(08)61854-5 |
0.411 |
|
| 2007 |
Corn PG, El-Deiry WS. Microarray analysis of p53-dependent gene expression in response to hypoxia and DNA damage. Cancer Biology & Therapy. 6: 1858-66. PMID 18087215 DOI: 10.4161/Cbt.6.12.5330 |
0.446 |
|
| 2007 |
El-Deiry WS. Targeting mutant p53 shows promise for sunscreens and skin cancer. The Journal of Clinical Investigation. 117: 3658-60. PMID 18060027 DOI: 10.1172/Jci34251 |
0.433 |
|
| 2007 |
Scata KA, El-Deiry WS. p53, BRCA1 and breast Cancer chemoresistance. Advances in Experimental Medicine and Biology. 608: 70-86. PMID 17993233 DOI: 10.1007/978-0-387-74039-3_5 |
0.429 |
|
| 2007 |
Yang W, El-Deiry WS. CARPs are E3 ligases that target apical caspases and p53. Cancer Biology & Therapy. 6: 1676-83. PMID 17986872 DOI: 10.4161/Cbt.6.11.4939 |
0.486 |
|
| 2007 |
Okawa T, Michaylira CZ, Kalabis J, Stairs DB, Nakagawa H, Andl CD, Johnstone CN, Klein-Szanto AJ, El-Deiry WS, Cukierman E, Herlyn M, Rustgi AK. The functional interplay between EGFR overexpression, hTERT activation, and p53 mutation in esophageal epithelial cells with activation of stromal fibroblasts induces tumor development, invasion, and differentiation. Genes & Development. 21: 2788-803. PMID 17974918 DOI: 10.1101/Gad.1544507 |
0.461 |
|
| 2007 |
Maniar TN, Braunstein I, Keefe S, Hussen S, Abrams T, De Michele A, El-Deiry WS. Childhood ALL and second neoplasms. Cancer Biology & Therapy. 6: 1525-31. PMID 17952026 DOI: 10.4161/Cbt.6.10.4928 |
0.321 |
|
| 2007 |
Wang S, Mintz A, Mochizuki K, Dorsey JF, Ackermann JM, Alavi A, El-Deiry WS. Multimodality optical imaging and 18F-FDG uptake in wild-type p53-containing and p53-null human colon tumor xenografts. Cancer Biology & Therapy. 6: 1649-53. PMID 17932466 DOI: 10.4161/Cbt.6.10.4948 |
0.417 |
|
| 2007 |
Matthew EM, Yen TJ, Dicker DT, Dorsey JF, Yang W, Navaraj A, El-Deiry WS. Replication stress, defective S-phase checkpoint and increased death in Plk2-deficient human cancer cells. Cell Cycle (Georgetown, Tex.). 6: 2571-8. PMID 17912033 DOI: 10.4161/Cc.6.20.5079 |
0.47 |
|
| 2007 |
Tavaluc RT, Hart LS, Dicker DT, El-Deiry WS. Effects of low confluency, serum starvation and hypoxia on the side population of cancer cell lines. Cell Cycle (Georgetown, Tex.). 6: 2554-62. PMID 17912032 DOI: 10.4161/Cc.6.20.4911 |
0.442 |
|
| 2007 |
Dicker DT, Lerner JM, El-Deiry WS. Hyperspectral image analysis of live cells in various cell cycle stages. Cell Cycle (Georgetown, Tex.). 6: 2563-70. PMID 17912031 DOI: 10.4161/Cc.6.20.4912 |
0.335 |
|
| 2007 |
Plastaras JP, Kim SH, Liu YY, Dicker DT, Dorsey JF, McDonough J, Cerniglia G, Rajendran RR, Gupta A, Rustgi AK, Diehl JA, Smith CD, Flaherty KT, El-Deiry WS. Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation. Cancer Research. 67: 9443-54. PMID 17909054 DOI: 10.1158/0008-5472.Can-07-1473 |
0.432 |
|
| 2007 |
Sussman RT, Ricci MS, Hart LS, Sun SY, El-Deiry WS. Chemotherapy-resistant side-population of colon cancer cells has a higher sensitivity to TRAIL than the non-SP, a higher expression of c-Myc and TRAIL-receptor DR4. Cancer Biology & Therapy. 6: 1490-5. PMID 17881904 DOI: 10.4161/Cbt.6.9.4905 |
0.451 |
|
| 2007 |
Ricci MS, Kim SH, Ogi K, Plastaras JP, Ling J, Wang W, Jin Z, Liu YY, Dicker DT, Chiao PJ, Flaherty KT, Smith CD, El-Deiry WS. Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. Cancer Cell. 12: 66-80. PMID 17613437 DOI: 10.1016/J.Ccr.2007.05.006 |
0.653 |
|
| 2007 |
Takaoka M, Kim SH, Okawa T, Michaylira CZ, Stairs DB, Johnstone CN, Andl CD, Rhoades B, Lee JJ, Klein-Szanto AJ, El-Deiry WS, Nakagawa H. IGFBP-3 regulates esophageal tumor growth through IGF-dependent and independent mechanisms. Cancer Biology & Therapy. 6: 534-40. PMID 17457048 DOI: 10.4161/Cbt.6.4.3832 |
0.397 |
|
| 2007 |
Lioni M, Brafford P, Andl C, Rustgi A, El-Deiry W, Herlyn M, Smalley KS. Dysregulation of claudin-7 leads to loss of E-cadherin expression and the increased invasion of esophageal squamous cell carcinoma cells. The American Journal of Pathology. 170: 709-21. PMID 17255337 DOI: 10.2353/Ajpath.2007.060343 |
0.366 |
|
| 2007 |
Yang W, Rozan LM, McDonald ER, Navaraj A, Liu JJ, Matthew EM, Wang W, Dicker DT, El-Deiry WS. CARPs are ubiquitin ligases that promote MDM2-independent p53 and phospho-p53ser20 degradation. The Journal of Biological Chemistry. 282: 3273-81. PMID 17121812 DOI: 10.1074/Jbc.M610793200 |
0.781 |
|
| 2007 |
Rozan LM, El-Deiry WS. p53 downstream target genes and tumor suppression: a classical view in evolution. Cell Death and Differentiation. 14: 3-9. PMID 17068503 DOI: 10.1038/Sj.Cdd.4402058 |
0.385 |
|
| 2007 |
El-Deiry WS. In memory of Russell Klein, Ph.D.: 1962-2006 Cancer Biology and Therapy. 6: 131. DOI: 10.4161/Cbt.6.2.3844 |
0.34 |
|
| 2007 |
El-Deiry WS. Cancer Biology & Therapy Celebrates Five Years of Publication Cancer Biology & Therapy. 6: 9-10. DOI: 10.4161/Cbt.6.1.3785 |
0.358 |
|
| 2006 |
Grimberg A, Coleman CM, Shi Z, Burns TF, MacLachlan TK, Wang W, El-Deiry WS. Insulin-like growth factor factor binding protein-2 is a novel mediator of p53 inhibition of insulin-like growth factor signaling. Cancer Biology & Therapy. 5: 1408-14. PMID 17102589 DOI: 10.4161/Cbt.5.10.3455 |
0.411 |
|
| 2006 |
Kim SH, Nakagawa H, Navaraj A, Naomoto Y, Klein-Szanto AJ, Rustgi AK, El-Deiry WS. Tumorigenic conversion of primary human esophageal epithelial cells using oncogene combinations in the absence of exogenous Ras. Cancer Research. 66: 10415-24. PMID 17079462 DOI: 10.1158/0008-5472.Can-06-2104 |
0.409 |
|
| 2006 |
Scata KA, El-Deiry WS. Taming NEMO to slay cancer cells. Cancer Biology & Therapy. 5: 1096-7. PMID 17012852 DOI: 10.4161/Cbt.5.9.3341 |
0.353 |
|
| 2006 |
Rozan LM, El-Deiry WS. Identification and characterization of proteins interacting with Traf4, an enigmatic p53 target. Cancer Biology & Therapy. 5: 1228-35. PMID 16969126 DOI: 10.4161/Cbt.5.9.3295 |
0.39 |
|
| 2006 |
Jin Z, El-Deiry WS. Distinct signaling pathways in TRAIL- versus tumor necrosis factor-induced apoptosis. Molecular and Cellular Biology. 26: 8136-48. PMID 16940186 DOI: 10.1128/Mcb.00257-06 |
0.639 |
|
| 2006 |
Mayes PA, El-Deiry WS. The complementary roles of the extrinsic and intrinsic apoptotic pathways in promoting the death of cancer cells. Cancer Journal (Sudbury, Mass.). 12: 247-9. PMID 16925967 DOI: 10.1097/00130404-200607000-00001 |
0.679 |
|
| 2006 |
Kuribayashi K, Mayes PA, El-Deiry WS. What are caspases 3 and 7 doing upstream of the mitochondria? Cancer Biology & Therapy. 5: 763-5. PMID 16921264 DOI: 10.4161/Cbt.5.7.3228 |
0.626 |
|
| 2006 |
Finnberg N, El-Deiry WS. Selective TRAIL-induced apoptosis in dysplastic neoplasia of the colon may lead to new neoadjuvant or adjuvant therapies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 4132-6. PMID 16857782 DOI: 10.1158/1078-0432.Ccr-06-0567 |
0.433 |
|
| 2006 |
Wang S, El-Deiry WS. p73 or p53 directly regulates human p53 transcription to maintain cell cycle checkpoints. Cancer Research. 66: 6982-9. PMID 16849542 DOI: 10.1158/0008-5472.Can-06-0511 |
0.395 |
|
| 2006 |
Tang J, Qu LK, Zhang J, Wang W, Michaelson JS, Degenhardt YY, El-Deiry WS, Yang X. Critical role for Daxx in regulating Mdm2. Nature Cell Biology. 8: 855-62. PMID 16845383 DOI: 10.1038/Ncb1442 |
0.426 |
|
| 2006 |
Wang W, Kim SH, El-Deiry WS. Small-molecule modulators of p53 family signaling and antitumor effects in p53-deficient human colon tumor xenografts Proceedings of the National Academy of Sciences of the United States of America. 103: 11003-11008. PMID 16835297 DOI: 10.1073/Pnas.0604507103 |
0.488 |
|
| 2006 |
El-Deiry WS. Lobbying congress to make cancer funding a priority: What scientists can do Cancer Biology and Therapy. 5: 467-469. PMID 16721038 DOI: 10.4161/Cbt.5.5.2837 |
0.308 |
|
| 2006 |
El-Deiry WS, Rustgi AK. Cancer Biology: A new discipline with required reading Cancer Biology & Therapy. 5: 1415-1415. DOI: 10.4161/Cbt.5.10.3441 |
0.318 |
|
| 2006 |
Zhou L, Moon L, Ranji M, Li L, Zhong B, Blessington D, Glickson J, El-Deiry W, Chance B. Novel fluorochromes for functional imaging of cancer Optics Infobase Conference Papers. DOI: 10.1364/Bio.2006.Sg6 |
0.334 |
|
| 2006 |
Plastaras JP, Dorsey JF, Carroll K, Kim SH, Birnbaum MJ, El-Deiry WS. Abstract217: Role of PI3K/Akt Signaling in TRAIL- and Radiation-Induced Gastrointestinal Apoptosis International Journal of Radiation Oncology Biology Physics. 66. DOI: 10.1016/J.Ijrobp.2006.07.250 |
0.331 |
|
| 2005 |
Navaraj A, Mori T, El-Deiry WS. Cooperation between BRCA1 and p53 in repair of cyclobutane pyrimidine dimers Cancer Biology and Therapy. 4: 1409-1414. PMID 16357511 DOI: 10.4161/Cbt.4.12.2378 |
0.411 |
|
| 2005 |
Corn PG, Ricci MS, Scata KA, Arsham AM, Simon MC, Dicker DT, El-Deiry WS. Mxi1 is induced by hypoxia in a HIF-1-dependent manner and protects cells from c-Myc-induced apoptosis. Cancer Biology & Therapy. 4: 1285-94. PMID 16319523 DOI: 10.4161/Cbt.4.11.2299 |
0.357 |
|
| 2005 |
Mayes PA, Campbell L, Ricci MS, Plastaras JP, Dicker DT, El-Deiry WS. Modulation of TRAIL-induced tumor cell apoptosis in a hypoxic environment. Cancer Biology & Therapy. 4: 1068-74. PMID 16294025 DOI: 10.4161/Cbt.4.10.2255 |
0.688 |
|
| 2005 |
Finnberg N, Kim SH, Furth EE, Liu JJ, Russo P, Piccoli DA, Grimberg A, El-Deiry WS. Non-invasive fluorescence imaging of cell death in fresh human colon epithelia treated with 5-Fluorouracil, CPT-11 and/or TRAIL. Cancer Biology & Therapy. 4: 937-42. PMID 16251801 DOI: 10.4161/Cbt.4.9.2182 |
0.431 |
|
| 2005 |
Dicker DT, Kim SH, Jin Z, El-Deiry WS. Heterogeneity in non-invasive detection of apoptosis among human tumor cell lines using annexin-V tagged with EGFP or Qdot-705. Cancer Biology & Therapy. 4: 1014-7. PMID 16222122 DOI: 10.4161/Cbt.4.9.2150 |
0.66 |
|
| 2005 |
Takaoka M, Smith CE, Mashiba MK, Okawa T, Andl CD, El-Deiry WS, Nakagawa H. EGF-mediated regulation of IGFBP-3 determines esophageal epithelial cellular response to IGF-I. American Journal of Physiology. Gastrointestinal and Liver Physiology. 290: G404-16. PMID 16210470 DOI: 10.1152/Ajpgi.00344.2005 |
0.369 |
|
| 2005 |
Wang W, Ho WC, Dicker DT, MacKinnon C, Winkler JD, Marmorstein R, El-Deiry WS. Acridine derivatives activate p53 and induce tumor cell death through Bax. Cancer Biology & Therapy. 4: 893-8. PMID 16177561 DOI: 10.4161/Cbt.4.8.2134 |
0.481 |
|
| 2005 |
Liu JJ, Wang W, Dicker DT, El-Deiry WS. Bioluminescent imaging of TRAIL-induced apoptosis through detection of caspase activation following cleavage of DEVD-aminoluciferin Cancer Biology &Amp; Therapy.. 4: 885-892. PMID 16177559 DOI: 10.4161/Cbt.4.8.2133 |
0.452 |
|
| 2005 |
Wang J, Devgan V, Corrado M, Prabhu NS, El-Deiry WS, Riccardi C, Pandolfi PP, Missero C, Dotto GP. Glucocorticoid-induced tumor necrosis factor receptor is a p21Cip1/WAF1 transcriptional target conferring resistance of keratinocytes to UV light-induced apoptosis. The Journal of Biological Chemistry. 280: 37725-31. PMID 16155000 DOI: 10.1074/Jbc.M507976200 |
0.453 |
|
| 2005 |
El-Deiry WS. Plagiarism is not acceptable in science or for cancer biology & therapy Cancer Biology and Therapy. 4: 619-620. PMID 16082228 DOI: 10.4161/Cbt.4.6.1875 |
0.305 |
|
| 2005 |
El-Deiry WS. Meeting report: The international conference on tumor progression and therapeutic resistance Cancer Research. 65: 4475-4484. PMID 15930261 DOI: 10.1158/0008-5472.Can-05-0620 |
0.397 |
|
| 2005 |
Dash BC, El-Deiry WS. Phosphorylation of p21 in G 2/M promotes cyclin B-Cdc2 kinase activity Molecular and Cellular Biology. 25: 3364-3387. PMID 15798220 DOI: 10.1128/Mcb.25.8.3364-3387.2005 |
0.314 |
|
| 2005 |
Grimberg A, Coleman CM, Burns TF, Himelstein BP, Koch CJ, Cohen P, El-Deiry WS. p53-Dependent and p53-independent induction of insulin-like growth factor binding protein-3 by deoxyribonucleic acid damage and hypoxia. The Journal of Clinical Endocrinology and Metabolism. 90: 3568-74. PMID 15769996 DOI: 10.1210/Jc.2004-1213 |
0.448 |
|
| 2005 |
Jin Z, El-Deiry WS. Overview of cell death signaling pathways. Cancer Biology & Therapy. 4: 139-63. PMID 15725726 DOI: 10.4161/Cbt.4.2.1508 |
0.635 |
|
| 2005 |
Finnberg N, Gruber JJ, Fei P, Rudolph D, Bric A, Kim SH, Burns TF, Ajuha H, Page R, Wu GS, Chen Y, McKenna WG, Bernhard E, Lowe S, Mak T, ... El-Deiry WS, et al. DR5 knockout mice are compromised in radiation-induced apoptosis. Molecular and Cellular Biology. 25: 2000-13. PMID 15713653 DOI: 10.1128/Mcb.25.5.2000-2013.2005 |
0.427 |
|
| 2005 |
Finnberg N, El-Deiry WS. Paclitaxel and Velcade: The rationale for a combo Cancer Biology and Therapy. 4: 631-634. DOI: 10.4161/Cbt.4.6.1866 |
0.457 |
|
| 2005 |
Wang S, El-Deiry WS. P53, cell cycle arrest and apoptosis 25 Years of P53 Research. 141-163. DOI: 10.1007/978-1-4020-2922-6_6 |
0.338 |
|
| 2004 |
Lin SW, Cook M, Finnberg N, Bernhard E, Baldwin D, El-Deiry WS. p53-dependent induction of serine proteases in irradiated mouse colon. Cancer Biology & Therapy. 3: 1290-7. PMID 15684611 DOI: 10.4161/Cbt.3.12.1448 |
0.402 |
|
| 2004 |
Fei P, Wang W, Kim SH, Wang S, Burns TF, Sax JK, Buzzai M, Dicker DT, McKenna WG, Bernhard EJ, El-Deiry WS. Bnip3L is induced by p53 under hypoxia, and its knockdown promotes tumor growth. Cancer Cell. 6: 597-609. PMID 15607964 DOI: 10.1016/J.Ccr.2004.10.012 |
0.81 |
|
| 2004 |
Tibbetts MD, Shiozaki EN, Gu L, McDonald ER, El-Deiry WS, Shi Y. Crystal structure of a FYVE-type zinc finger domain from the caspase regulator CARP2. Structure (London, England : 1993). 12: 2257-63. PMID 15576038 DOI: 10.1016/J.Str.2004.10.007 |
0.679 |
|
| 2004 |
Takaoka M, Harada H, Andl CD, Oyama K, Naomoto Y, Dempsey KL, Klein-Szanto AJ, El-Deiry WS, Grimberg A, Nakagawa H. Epidermal growth factor receptor regulates aberrant expression of insulin-like growth factor-binding protein 3. Cancer Research. 64: 7711-23. PMID 15520175 DOI: 10.1158/0008-5472.Can-04-0715 |
0.387 |
|
| 2004 |
Wang S, El-Deiry WS. Inducible silencing of KILLER/DR5 in vivo promotes bioluminescent colon tumor xenograft growth and confers resistance to chemotherapeutic agent 5-fluorouracil Cancer Research. 64: 6666-6672. PMID 15374982 DOI: 10.1158/0008-5472.Can-04-1734 |
0.495 |
|
| 2004 |
Ricci MS, Jin Z, Dews M, Yu D, Thomas-Tikhonenko A, Dicker DT, El-Deiry WS. Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity. Molecular and Cellular Biology. 24: 8541-55. PMID 15367674 DOI: 10.1128/Mcb.24.19.8541-8555.2004 |
0.758 |
|
| 2004 |
Wang W, El-Deiry WS. Targeting p53 by PTD-mediated transduction Trends in Biotechnology. 22: 431-434. PMID 15331219 DOI: 10.1016/J.Tibtech.2004.07.002 |
0.431 |
|
| 2004 |
Shah R, El-Deiry WS. p53-dependent activation of a molecular beacon in tumor cells following exposure to doxorubicin chemotherapy Cancer Biology and Therapy. 3: 871-875. PMID 15254427 DOI: 10.4161/Cbt.3.9.1053 |
0.489 |
|
| 2004 |
Finnberg N, El-Deiry WS. Activating FOXO3a, NF-κB and p53 by targeting IKKs: An effective multi-faceted targeting of the tumor-cell phenotype? Cancer Biology and Therapy. 3: 614-616. PMID 15254408 DOI: 10.4161/Cbt.3.7.1057 |
0.48 |
|
| 2004 |
Kim SH, Kim K, Kwagh JG, Dicker DT, Herlyn M, Rustgi AK, Chen Y, El-Deiry WS. Death induction by recombinant native TRAIL and its prevention by a caspase 9 inhibitor in primary human esophageal epithelial cells Journal of Biological Chemistry. 279: 40044-40052. PMID 15226295 DOI: 10.1074/Jbc.M404541200 |
0.465 |
|
| 2004 |
Dash BC, El-Deiry WS. Cell cycle checkpoint control mechanisms that can be disrupted in cancer Methods in Molecular Biology (Clifton, N.J.). 280: 99-161. PMID 15187251 DOI: 10.1385/1-59259-788-2:099 |
0.422 |
|
| 2004 |
Wang S, El-Deiry WS. The p53 pathway: targets for the development of novel cancer therapeutics Cancer Treatment and Research. 119: 175-187. PMID 15164878 DOI: 10.1007/1-4020-7847-1_9 |
0.409 |
|
| 2004 |
Jin Z, McDonald ER, Dicker DT, El-Deiry WS. Deficient tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor transport to the cell surface in human colon cancer cells selected for resistance to TRAIL-induced apoptosis. The Journal of Biological Chemistry. 279: 35829-39. PMID 15155747 DOI: 10.1074/Jbc.M405538200 |
0.806 |
|
| 2004 |
Scata KA, El-Deiry WS. Zebrafish: Swimming towards a role for fanconi genes in DNA repair Cancer Biology and Therapy. 3: 501-502. PMID 15136765 DOI: 10.4161/Cbt.3.6.946 |
0.323 |
|
| 2004 |
Thomas-Tikhonenko A, Viard-Leveugle I, Dews M, Wehrli P, Sevignani C, Yu D, Ricci S, el-Deiry W, Aronow B, Kaya G, Saurat JH, French LE. Myc-transformed epithelial cells down-regulate clusterin, which inhibits their growth in vitro and carcinogenesis in vivo. Cancer Research. 64: 3126-36. PMID 15126350 DOI: 10.1158/0008-5472.Can-03-1953 |
0.666 |
|
| 2004 |
Wang W, El-Deiry WS. Targeting FOXO Kills Two Birds with One Stone Chemistry and Biology. 11: 16-18. PMID 15112990 DOI: 10.1016/J.Chembiol.2004.01.011 |
0.346 |
|
| 2004 |
McDonald ER, El-Deiry WS. Suppression of caspase-8- and -10-associated RING proteins results in sensitization to death ligands and inhibition of tumor cell growth. Proceedings of the National Academy of Sciences of the United States of America. 101: 6170-5. PMID 15069192 DOI: 10.1073/Pnas.0307459101 |
0.776 |
|
| 2004 |
Kim K, Nakagawa H, Fei P, Rustgi AK, El-Deiry WS. Targeting Bcl-XL in esophageal squamous cancer to sensitize to chemotherapy plus TRAIL-induced apoptosis while normal epithelial cells are protected by blockade of caspase 9 Cell Death and Differentiation. 11: 583-587. PMID 14752513 DOI: 10.1038/Sj.Cdd.4401388 |
0.454 |
|
| 2004 |
Wang S, El-Deiry WS. Cytochrome c: A crosslink between the mitochondria and the endoplasmic reticulum in calcium-dependent apoptosis Cancer Biology and Therapy. 3: 44-46. PMID 14726686 DOI: 10.4161/Cbt.3.1.740 |
0.318 |
|
| 2004 |
Dicker DT, El-Deiry WS. Flow cytometric analysis of cell cycle control by tumor suppressor genes. Methods in Molecular Biology (Clifton, N.J.). 223: 211-5. PMID 12777732 DOI: 10.1385/1-59259-329-1:211 |
0.337 |
|
| 2003 |
Rikhof B, Corn PG, El-Deiry WS. Caspase 10 levels are increased following DNA damage in a p53-dependent manner Cancer Biology and Therapy. 2: 707-712. PMID 14688482 DOI: 10.4161/Cbt.2.6.626 |
0.426 |
|
| 2003 |
Wang S, El-Deiry WS. Requirement of p53 targets in chemosensitization of colonic carcinoma to death ligand therapy Proceedings of the National Academy of Sciences of the United States of America. 100: 15095-15100. PMID 14645705 DOI: 10.1073/Pnas.2435285100 |
0.52 |
|
| 2003 |
Wang S, El-Deiry WS. TRAIL and apoptosis induction by TNF-family death receptors Oncogene. 22: 8628-8633. PMID 14634624 DOI: 10.1038/Sj.Onc.1207232 |
0.501 |
|
| 2003 |
Das S, El-Deiry WS, Somasundaram K. Efficient growth inhibition of HPV 16 E6-expressing cells by an adenovirus-expressing p53 homologue p73β Oncogene. 22: 8394-8402. PMID 14627980 DOI: 10.1038/Sj.Onc.1206908 |
0.422 |
|
| 2003 |
El-Deiry WS. The role of p53 in chemosensitivity and radiosensitivity Oncogene. 22: 7486-7495. PMID 14576853 DOI: 10.1038/Sj.Onc.1206949 |
0.464 |
|
| 2003 |
Corn PG, McDonald ER, Herman JG, El-Deiry WS. Tat-binding protein-1, a component of the 26S proteasome, contributes to the E3 ubiquitin ligase function of the von Hippel-Lindau protein. Nature Genetics. 35: 229-37. PMID 14556007 DOI: 10.1038/Ng1254 |
0.691 |
|
| 2003 |
Burns TF, El-Deiry WS. Microarray analysis of p53 target gene expression patterns in the spleen and thymus in response to ionizing radiation Cancer Biology and Therapy. 2: 431-443. PMID 14508117 DOI: 10.4161/Cbt.2.4.478 |
0.439 |
|
| 2003 |
Sax JK, Stoddard A, Murphy ME, Chodosh L, El-Deiry WS. Microarray expression profiling of p53-dependent transcriptional changes in an immortalized mouse embryo fibroblast cell line. Cancer Biology & Therapy. 2: 416-30. PMID 14508116 DOI: 10.4161/Cbt.2.4.477 |
0.794 |
|
| 2003 |
Wang W, Rastinejad F, El-Deiry WS. Restoring p53-dependent tumor suppression. Cancer Biology & Therapy. 2: S55-63. PMID 14508081 DOI: 10.4161/Cbt.203 |
0.475 |
|
| 2003 |
Choi EA, Lei H, Maron DJ, Wilson JM, Barsoum J, Fraker DL, El-Deiry WS, Spitz FR. Stat1-dependent induction of tumor necrosis factor-related apoptosis-inducing ligand and the cell-surface death signaling pathway by interferon beta in human cancer cells. Cancer Research. 63: 5299-307. PMID 14500361 |
0.359 |
|
| 2003 |
Fei P, El-Deiry WS. P53 and radiation responses Oncogene. 22: 5774-5783. PMID 12947385 DOI: 10.1038/Sj.Onc.1206677 |
0.469 |
|
| 2003 |
Burns TF, Fei P, Scata KA, Dicker DT, El-Deiry WS. Silencing of the novel p53 target gene Snk/Plk2 leads to mitotic catastrophe in paclitaxel (taxol)-exposed cells. Molecular and Cellular Biology. 23: 5556-71. PMID 12897130 DOI: 10.1128/Mcb.23.16.5556-5571.2003 |
0.503 |
|
| 2003 |
Sax JK, El-Deiry WS. p53-induced gene expression analysis. Methods in Molecular Biology (Clifton, N.J.). 234: 65-71. PMID 12824525 DOI: 10.1385/1-59259-408-5:65 |
0.746 |
|
| 2003 |
Sax JK, El-Deiry WS. Identification and characterization of the cytoplasmic protein TRAF4 as a p53-regulated proapoptotic gene. The Journal of Biological Chemistry. 278: 36435-44. PMID 12788948 DOI: 10.1074/Jbc.M303191200 |
0.797 |
|
| 2003 |
Dicker DT, El-Deiry WS. Flow cytometric analysis of tumor suppressor gene-induced apoptosis. Methods of Molecular Biology. 223: 271-282. PMID 12777737 DOI: 10.1385/1-59259-329-1:271 |
0.382 |
|
| 2003 |
McDonald ER, El-Deiry WS. Yeast two-hybrid screening as a means of deciphering tumor suppressor pathways. Methods in Molecular Biology (Clifton, N.J.). 223: 173-85. PMID 12777729 DOI: 10.1385/1-59259-329-1:173 |
0.717 |
|
| 2003 |
MacLachlan TK, El-Deiry WS. Identification of DNA-binding of tumor suppressor genes by chromatin immunoprecipitation. Methods of Molecular Biology. 223: 129-133. PMID 12777725 DOI: 10.1385/1-59259-329-1:129 |
0.312 |
|
| 2003 |
Wang W, El-Deiry WS. Bioluminescent molecular imaging of endogenous and exogenous p53-mediated transcription in vitro and in vivo using an HCT116 human colon carcinoma xenograft model Cancer Biology and Therapy. 2: 196-202. PMID 12750563 DOI: 10.4161/Cbt.2.2.347 |
0.444 |
|
| 2003 |
Campling BG, El-Deiry WS. Clinical implication of p53 mutation in lung cancer Applied Biochemistry and Biotechnology - Part B Molecular Biotechnology. 24: 141-156. PMID 12746555 DOI: 10.1385/Mb:24:2:141 |
0.431 |
|
| 2003 |
Sax JK, El-Deiry WS. p53 downstream targets and chemosensitivity. Cell Death and Differentiation. 10: 413-7. PMID 12719718 DOI: 10.1038/Sj.Cdd.4401227 |
0.753 |
|
| 2003 |
Benezra M, Chevallier N, Morrison DJ, MacLachlan TK, El-Deiry WS, Licht JD. BRCA1 augments transcription by the NF-kappaB transcription factor by binding to the Rel domain of the p65/RelA subunit. The Journal of Biological Chemistry. 278: 26333-41. PMID 12700228 DOI: 10.1074/Jbc.M303076200 |
0.391 |
|
| 2003 |
Ozören N, El-Deiry WS. Cell surface Death Receptor signaling in normal and cancer cells. Seminars in Cancer Biology. 13: 135-47. PMID 12654257 DOI: 10.1016/S1044-579X(02)00131-1 |
0.78 |
|
| 2003 |
Gruss CJ, Satyamoorthy K, Berking C, Lininger J, Nesbit M, Schaider H, Liu ZJ, Oka M, Hsu MY, Shirakawa T, Li G, Bogenrieder T, Carmeliet P, El-Deiry WS, Eck SL, et al. Stroma formation and angiogenesis by overexpression of growth factors, cytokines, and proteolytic enzymes in human skin grafted to SCID mice. The Journal of Investigative Dermatology. 120: 683-92. PMID 12648235 DOI: 10.1046/J.1523-1747.2003.12112.X |
0.32 |
|
| 2003 |
Das S, El-Deiry WS, Somasundaram K. Regulation of the p53 homolog p73 by adenoviral oncogene E1A Journal of Biological Chemistry. 278: 18313-18320. PMID 12639967 DOI: 10.1074/Jbc.M211704200 |
0.404 |
|
| 2003 |
Burns TF, el-Deiry WS. Cell death signaling in maligancy Cancer Treatment and Research. 115: 319-343. PMID 12613203 DOI: 10.1007/0-306-48158-8_13 |
0.353 |
|
| 2003 |
Wang W, Takimoto R, Rastinejad F, El-Deiry WS. Stabilization of p53 by CP-31398 inhibits ubiquitination without altering phosphorylation at serine 15 or 20 or MDM2 binding. Molecular and Cellular Biology. 23: 2171-81. PMID 12612087 DOI: 10.1128/Mcb.23.6.2171-2181.2003 |
0.461 |
|
| 2003 |
Corn PG, Summers MK, Fogt F, Virmani AK, Gazdar AF, Halazonetis TD, El-Deiry WS. Frequent hypermethylation of the 5' CpG island of the mitotic stress checkpoint gene Chfr in colorectal and non-small cell lung cancer. Carcinogenesis. 24: 47-51. PMID 12538348 DOI: 10.1093/Carcin/24.1.47 |
0.396 |
|
| 2003 |
Campling BG, el-Deiry WS. Clinical implications of p53 mutations in lung cancer Methods in Molecular Medicine. 75: 53-77. PMID 12407735 DOI: 10.1385/1-59259-324-0:53 |
0.415 |
|
| 2002 |
Fei P, Bernhard EJ, El-Deiry WS. Tissue-specific induction of p53 targets in vivo Cancer Research. 62: 7316-7327. PMID 12499275 |
0.343 |
|
| 2002 |
El-Deiry WS. Transactivation of repair genes by BRCA1. Cancer Biology & Therapy. 1: 490-491. PMID 12496474 DOI: 10.4161/Cbt.1.5.162 |
0.365 |
|
| 2002 |
Ozören N, El-Deiry W. Heat shock protects HCT116 and H460 cells from TRAIL-induced apoptosis. Experimental Cell Research. 281: 175-81. PMID 12460647 DOI: 10.1006/Excr.2002.5660 |
0.768 |
|
| 2002 |
Sax JK, Dash BC, Hong R, Dicker DT, El-Deiry WS. The cyclin-dependent kinase inhibitor butyrolactone is a potent inhibitor of p21 (WAF1/CIP1 expression). Cell Cycle (Georgetown, Tex.). 1: 90-6. PMID 12429914 |
0.782 |
|
| 2002 |
Jin Z, Dicker DT, El-Deiry WS. Enhanced sensitivity of G1 arrested human cancer cells suggests a novel therapeutic strategy using a combination of simvastatin and TRAIL. Cell Cycle (Georgetown, Tex.). 1: 82-9. PMID 12429913 DOI: 10.4161/Cc.1.1.104 |
0.659 |
|
| 2002 |
Ozören N, El-Deiry WS. Defining characteristics of Types I and II apoptotic cells in response to TRAIL. Neoplasia (New York, N.Y.). 4: 551-7. PMID 12407450 DOI: 10.1038/Sj.Neo.7900270 |
0.783 |
|
| 2002 |
Sax JK, Fei P, Murphy ME, Bernhard E, Korsmeyer SJ, El-Deiry WS. BID regulation by p53 contributes to chemosensitivity. Nature Cell Biology. 4: 842-9. PMID 12402042 DOI: 10.1038/Ncb866 |
0.797 |
|
| 2002 |
Venkataramani RN, MacLachlan TK, Chai X, El-Deiry WS, Marmorstein R. Structure-based design of p18INK4c proteins with increased thermodynamic stability and cell cycle inhibitory activity. The Journal of Biological Chemistry. 277: 48827-33. PMID 12370184 DOI: 10.1074/Jbc.M208061200 |
0.383 |
|
| 2002 |
Takimoto R, Wang W, Dicker DT, Rastinejad F, Lyssikatos J, el-Deiry WS. The mutant p53-conformation modifying drug, CP-31398, can induce apoptosis of human cancer cells and can stabilize wild-type p53 protein. Cancer Biology & Therapy. 1: 47-55. PMID 12174820 DOI: 10.4161/Cbt.1.1.41 |
0.515 |
|
| 2002 |
Takimoto R, MacLachlan TK, Dicker DT, Niitsu Y, Mori T, el-Deiry WS. BRCA1 transcriptionally regulates damaged DNA binding protein (DDB2) in the DNA repair response following UV-irradiation. Cancer Biology & Therapy. 1: 177-86. PMID 12170778 DOI: 10.4161/Cbt.65 |
0.389 |
|
| 2002 |
Campbell AM, Campling BG, Algazy KM, el-Deiry WS. Clinical and molecular features of small cell lung cancer. Cancer Biology & Therapy. 1: 105-12. PMID 12170769 DOI: 10.4161/Cbt.52 |
0.366 |
|
| 2002 |
Grimberg A, Liu B, Bannerman P, El-Deiry WS, Cohen P. IGFBP-3 mediates p53-induced apoptosis during serum starvation International Journal of Oncology. 21: 327-335. PMID 12118329 DOI: 10.3892/Ijo.21.2.327 |
0.449 |
|
| 2002 |
MacLachlan TK, El-Deiry WS. Apoptotic threshold is lowered by p53 transactivation of caspase-6 Proceedings of the National Academy of Sciences of the United States of America. 99: 9492-9497. PMID 12089322 DOI: 10.1073/Pnas.132241599 |
0.471 |
|
| 2002 |
MacLachlan TK, Takimoto R, El-Deiry WS. BRCA1 directs a selective p53-dependent transcriptional response towards growth arrest and DNA repair targets Molecular and Cellular Biology. 22: 4280-4292. PMID 12024039 DOI: 10.1128/Mcb.22.12.4280-4292.2002 |
0.454 |
|
| 2002 |
He Q, Lee DI, Rong R, Yu M, Luo X, Klein M, El-Deiry WS, Huang Y, Hussain A, Sheikh MS. Endoplasmic reticulum calcium pool depletion-induced apoptosis is coupled with activation of the death receptor 5 pathway. Oncogene. 21: 2623-33. PMID 11965535 DOI: 10.1038/Sj.Onc.1205345 |
0.414 |
|
| 2002 |
Corn PG, El-Deiry WS. Derangement of growth and differentiation control in oncogenesis Bioessays. 24: 83-90. PMID 11782953 DOI: 10.1002/Bies.10036 |
0.44 |
|
| 2002 |
El-Deiry WS. Introducing Cancer Biology & Therapy Cancer Biology & Therapy. 1: 2-2. DOI: 10.4161/Cbt.1.1.27 |
0.323 |
|
| 2001 |
Wang T, Kobayashi T, Takimoto R, Denes AE, Snyder EL, el-Deiry WS, Brachmann RK. hADA3 is required for p53 activity. The Embo Journal. 20: 6404-13. PMID 11707411 DOI: 10.1093/Emboj/20.22.6404 |
0.449 |
|
| 2001 |
El-Deiry WS. Insights into cancer therapeutic design based on p53 and TRAIL receptor signaling Cell Death and Differentiation. 8: 1066-1075. PMID 11687885 DOI: 10.1038/Sj.Cdd.4400943 |
0.516 |
|
| 2001 |
Göke R, Göke A, Göke B, El-Deiry WS, Chen Y. Pioglitazone inhibits growth of carcinoid cells and promotes TRAIL-induced apoptosis by induction of p21waf1/cip1 Digestion. 64: 75-80. PMID 11684819 DOI: 10.1159/000048843 |
0.484 |
|
| 2001 |
Higuchi H, Bronk SF, Takikawa Y, Werneburg N, Takimoto R, El-Deiry W, Gores GJ. The Bile Acid Glycochenodeoxycholate Induces TRAIL-Receptor 2/DR5 Expression and Apoptosis Journal of Biological Chemistry. 276: 38610-38618. PMID 11507096 DOI: 10.1074/Jbc.M105300200 |
0.407 |
|
| Show low-probability matches. |